Skip to Main Content

INFORMATION FOR

Ian Krop, MD, PhD

Associate Cancer Center Director, Clinical Research; Director, Clinical Trials Office; Chief Clinical Research Officer, Yale Cancer Center

Contact Information

Ian Krop, MD, PhD

Research Summary

His research efforts have advanced the field through clinical trials that define the next generation of therapies for patients. Dr. Krop serves as a member of the NCI Breast Cancer Steering Committee and the Data Monitoring Committee for ECOG/ACRIN. He also serves on the Data and Safety Monitoring Boards for multiple phase III trials.

Coauthors

Research Interests

Breast Diseases

Selected Publications

  • 191P Correlation of early change in standardized uptake value (SUV) on positron emission tomography (PET/CT) with recurrence-free survival (RFS) and overall survival (OS) in patients with primary operable HER2-positive breast cancer (TBCRC026)Hennessy M, Leal J, Huang C, Solnes L, Denbow R, Abramson V, Carey L, Liu M, Rimawi M, Specht J, Storniolo A, Valero V, Vaklavas C, Winer E, Krop I, Wolff A, Cimino-Mathews A, Wahl R, Stearns V, Connolly R. 191P Correlation of early change in standardized uptake value (SUV) on positron emission tomography (PET/CT) with recurrence-free survival (RFS) and overall survival (OS) in patients with primary operable HER2-positive breast cancer (TBCRC026) Annals Of Oncology 2022, 33: s623-s624. DOI: 10.1016/j.annonc.2022.07.226.
  • Abstract 5165: The genomic landscape and prognostic implications of somatic alterations in patients (pts) with ER+, HER2-, PIK3CA mutated (mut) advanced breast cancer treated with taselisib and fulvestrantChen J, Dent S, Jacot W, Cortés J, Krop I, Stout T, Schimmoller F, Savage H, Hutchinson K, Wilson T. Abstract 5165: The genomic landscape and prognostic implications of somatic alterations in patients (pts) with ER+, HER2-, PIK3CA mutated (mut) advanced breast cancer treated with taselisib and fulvestrant Cancer Research 2022, 82: 5165-5165. DOI: 10.1158/1538-7445.am2022-5165.
  • Circulating tumor DNA (ctDNA) and late recurrence in high-risk, hormone receptor–positive, HER2-negative breast cancer (CHiRP).Lipsyc-Sharf M, De Bruin E, Santos K, McEwen R, Stetson D, Patel A, Kirkner G, Hughes M, Tolaney S, Krop I, Knape C, Feger U, Marsico G, Howarth K, Winer E, Lin N, Parsons H. Circulating tumor DNA (ctDNA) and late recurrence in high-risk, hormone receptor–positive, HER2-negative breast cancer (CHiRP). Journal Of Clinical Oncology 2022, 40: 103-103. DOI: 10.1200/jco.2022.40.16_suppl.103.
  • Results from the phase 1/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC).Krop I, Masuda N, Mukohara T, Takahashi S, Nakayama T, Inoue K, Iwata H, Toyama T, Yamamoto Y, Hansra D, Takahashi M, Osaki A, Koyama K, Inoue T, Yonekura T, Mostillo J, Ohwada S, Tanaka Y, Sternberg D, Yonemori K. Results from the phase 1/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC). Journal Of Clinical Oncology 2022, 40: 1002-1002. DOI: 10.1200/jco.2022.40.16_suppl.1002.
  • Long-term safety of inavolisib (GDC-0077) in an ongoing phase 1/1b study evaluating monotherapy and in combination (combo) with palbociclib and/or endocrine therapy in patients (pts) with PIK3CA -mutated, hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (BC).Bedard P, Accordino M, Cervantes A, Gambardella V, Hamilton E, Italiano A, Juric D, Kalinsky K, Krop I, Oliveira M, Saura C, Schmid P, Turner N, Varga A, Shankar N, Schutzman J, Royer-Joo S, Martin M, Jhaveri K. Long-term safety of inavolisib (GDC-0077) in an ongoing phase 1/1b study evaluating monotherapy and in combination (combo) with palbociclib and/or endocrine therapy in patients (pts) with PIK3CA -mutated, hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (BC). Journal Of Clinical Oncology 2022, 40: 1052-1052. DOI: 10.1200/jco.2022.40.16_suppl.1052.
  • Clinical outcomes with alpelisib (ALP) plus fulvestrant (FUL) after prior treatment (tx) with FUL in patients (pts) with advanced breast cancer (ABC): A real-world (RW) analysis.O'Shaughnessy J, Woeckel A, Pistilli B, Hegg R, Vahdat L, Vuina D, Asad ZVK P, Smith T, Kim J, Krop I. Clinical outcomes with alpelisib (ALP) plus fulvestrant (FUL) after prior treatment (tx) with FUL in patients (pts) with advanced breast cancer (ABC): A real-world (RW) analysis. Journal Of Clinical Oncology 2022, 40: 1055-1055. DOI: 10.1200/jco.2022.40.16_suppl.1055.
  • Longitudinal circulating tumor DNA (ctDNA) whole-exome sequencing (WES) in the phase Ib/II trial of palbociclib and bazedoxifene reveals genomic dynamics and clonal evolution with the acquisition of treatment resistance in hormone receptor-positive, HER2-negative (HR+ HER2-), advanced breast cancer (ABC).Grinshpun A, Tsuji J, Li T, Russo D, Anderson L, Rees R, Cibulskis C, Leshchiner I, Stewart C, Tung N, Krop I, Winer E, Tolaney S, Getz G, Jeselsohn R. Longitudinal circulating tumor DNA (ctDNA) whole-exome sequencing (WES) in the phase Ib/II trial of palbociclib and bazedoxifene reveals genomic dynamics and clonal evolution with the acquisition of treatment resistance in hormone receptor-positive, HER2-negative (HR+ HER2-), advanced breast cancer (ABC). Journal Of Clinical Oncology 2022, 40: 1058-1058. DOI: 10.1200/jco.2022.40.16_suppl.1058.
  • Phase 2 trial of tucatinib plus trastuzumab deruxtecan in patients with HER2+ locally advanced or metastatic breast cancer with and without brain metastases (HER2CLIMB-04, trial in progress).Krop I, Carey L, Ramos J, Chen Y, Hamilton E. Phase 2 trial of tucatinib plus trastuzumab deruxtecan in patients with HER2+ locally advanced or metastatic breast cancer with and without brain metastases (HER2CLIMB-04, trial in progress). Journal Of Clinical Oncology 2022, 40: tps1111-tps1111. DOI: 10.1200/jco.2022.40.16_suppl.tps1111.
  • 175P Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): Subgroup analyses from the BYLieve studyCardoso F, Juric D, Lerebours F, Krop I, Borrego M, Neven P, Park Y, Yardley D, Jhaveri K, Arce C, Gu E, Akdere M, Rugo H. 175P Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): Subgroup analyses from the BYLieve study Annals Of Oncology 2022, 33: s206-s207. DOI: 10.1016/j.annonc.2022.03.194.
  • Aktualisierte Ergebnisse von Tucatinib versus Placebo in Kombination mit Trastuzumab und Capecitabin bei Patienten mit vorbehandeltem, metastasierten HER2-positiven Brustkrebs mit ZNS-Metastasen (HER2CLIMB)Greil R, Lin N, Murthy R, Abramson V, Anders C, Bachelot T, Bedard P, Borges V, Cameron D, Carey L, Chien A, Curigliano G, DiGiovanna M, Gelmon K, Hortobagyi G, Hurvitz S, Krop I, Loi S, Loibl S, Mueller V, Oliveira M, Paplomata E, Pegram M, Slamon D, Zelnak A, Ramos J, Feng W, Winer E. Aktualisierte Ergebnisse von Tucatinib versus Placebo in Kombination mit Trastuzumab und Capecitabin bei Patienten mit vorbehandeltem, metastasierten HER2-positiven Brustkrebs mit ZNS-Metastasen (HER2CLIMB) Geburtshilfe Und Frauenheilkunde 2022, 82: e4-e5. DOI: 10.1055/s-0042-1746156.
  • Abstract P2-07-03: Correlation of immune-related protein expression with hormone receptor (HR) status and pathologic response to neoadjuvant paclitaxel/trastuzumab/pertuzumab (THP) among patients with early-stage HER2+ breast cancerWaks A, Huang Y, Hether T, Ogayo E, Kadel S, Alberti J, Tolaney S, Krop I, Divakar P, Metzger O, O'Donnell M, Church S, Winer E, Guerriero J, Mittendorf E. Abstract P2-07-03: Correlation of immune-related protein expression with hormone receptor (HR) status and pathologic response to neoadjuvant paclitaxel/trastuzumab/pertuzumab (THP) among patients with early-stage HER2+ breast cancer Cancer Research 2022, 82: p2-07-03-p2-07-03. DOI: 10.1158/1538-7445.sabcs21-p2-07-03.
  • Abstract P5-13-15: High dimensional flow cytometric analysis or the peripheral immune profile and response to HER2-targeted antibody therapyOgayo E, Waks A, Rogers W, Ionita M, Adigwe K, Alberti J, Kadel S, Moore J, King T, Krop I, Tolaney S, Winer E, Guerriero J, Mittendorf E. Abstract P5-13-15: High dimensional flow cytometric analysis or the peripheral immune profile and response to HER2-targeted antibody therapy Cancer Research 2022, 82: p5-13-15-p5-13-15. DOI: 10.1158/1538-7445.sabcs21-p5-13-15.
  • Abstract PD4-04: Updated results of tucatinib vs placebo added to trastuzumab and capecitabine for patients with previously treated HER2-positive metastatic breast cancer with brain metastases (HER2CLIMB)Lin N, Murthy R, Abramson V, Anders C, Bachelot T, Bedard P, Borges V, Cameron D, Cameron D, Carey L, Chien A, Curigliano G, DiGiovanna M, Gelmon K, Hortobagyi G, Hurvitz S, Krop I, Loi S, Loibl S, Mueller V, Oliveira M, Paplomata E, Pegram M, Slamon D, Zelnak A, Ramos J, Feng W, Winer E. Abstract PD4-04: Updated results of tucatinib vs placebo added to trastuzumab and capecitabine for patients with previously treated HER2-positive metastatic breast cancer with brain metastases (HER2CLIMB) Cancer Research 2022, 82: pd4-04-pd4-04. DOI: 10.1158/1538-7445.sabcs21-pd4-04.
  • Abstract GS1-05: Datopotamab deruxtecan in advanced/metastatic HER2- breast cancer: Results from the phase 1 TROPION-PanTumor01 studyKrop I, Juric D, Shimizu T, Tolcher A, Spira A, Mukohara T, Lisberg A, Kogawa T, Papadopoulos K, Hamilton E, Damodaran S, Greenberg J, Gu W, Kobayashi F, Guevara F, Jikoh T, Kawasaki Y, Meric-Bernstam F, Bardia A. Abstract GS1-05: Datopotamab deruxtecan in advanced/metastatic HER2- breast cancer: Results from the phase 1 TROPION-PanTumor01 study Cancer Research 2022, 82: gs1-05-gs1-05. DOI: 10.1158/1538-7445.sabcs21-gs1-05.
  • Abstract OT1-13-01: HER2CLIMB-04: phase 2 trial of tucatinib + trastuzumab deruxtecan in patients with HER2+ locally advanced or metastatic breast cancer with and without brain metastases (trial in progress)Hamilton E, Carey L, Ramos J, Chen Y, Krop I. Abstract OT1-13-01: HER2CLIMB-04: phase 2 trial of tucatinib + trastuzumab deruxtecan in patients with HER2+ locally advanced or metastatic breast cancer with and without brain metastases (trial in progress) Cancer Research 2022, 82: ot1-13-01-ot1-13-01. DOI: 10.1158/1538-7445.sabcs21-ot1-13-01.
  • Abstract P2-12-18: A phase 2 study of neoadjuvant systemic therapy with eribulin followed by doxorubicin and cyclophosphamide for HER2-negative inflammatory breast cancerLynce F, Yeh E, Regan M, Qin L, Bay C, Krop I, Harrison B, Nakhlis F, Bellon J, Overmoyer B. Abstract P2-12-18: A phase 2 study of neoadjuvant systemic therapy with eribulin followed by doxorubicin and cyclophosphamide for HER2-negative inflammatory breast cancer Cancer Research 2022, 82: p2-12-18-p2-12-18. DOI: 10.1158/1538-7445.sabcs21-p2-12-18.
  • Abstract P2-13-25: A phase I dose-escalation study of DHES0815A, a HER2-targeting antibody-drug conjugate with a DNA monoalkylator payload, in patients with HER2-positive breast cancerKrop I, Hamilton E, Jung K, Modi S, Kalinsky K, Phillips G, Shi R, Monemi S, Mamounas M, Saad O, Choeurng V, Commerford R, Cho E, Ungewickell A, LoRusso P. Abstract P2-13-25: A phase I dose-escalation study of DHES0815A, a HER2-targeting antibody-drug conjugate with a DNA monoalkylator payload, in patients with HER2-positive breast cancer Cancer Research 2022, 82: p2-13-25-p2-13-25. DOI: 10.1158/1538-7445.sabcs21-p2-13-25.
  • Abstract P5-17-05: A phase I/Ib study of inavolisib (GDC-0077) in combination with fulvestrant in patients (pts) with PIK3CA -mutated hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancerJuric D, Bedard P, Cervantes A, Gambardella V, Oliveira M, Saura C, Kalinsky K, Hamilton E, Italiano A, Krop I, Schmid P, Turner N, Varga A, Royer-Joo S, Hutchinson K, Schutzman J, Jhaveri K. Abstract P5-17-05: A phase I/Ib study of inavolisib (GDC-0077) in combination with fulvestrant in patients (pts) with PIK3CA -mutated hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer Cancer Research 2022, 82: p5-17-05-p5-17-05. DOI: 10.1158/1538-7445.sabcs21-p5-17-05.
  • Abstract PD4-02: Safety and efficacy of a tucatinib-trastuzumab-capecitabine regimen for treatment of leptomeningeal metastasis (LM) in HER2-positive breast cancer: Results from TBCRC049, a phase 2 non-randomized studyMurthy R, O'Brien B, Berry D, Singareeka-Raghavendra A, Monroe M, Johnson J, White J, Childress J, Sanford J, Schwartz-Gomez J, Melisko M, Morikawa A, Ferguson S, de Groot J, Krop I, Valero V, Rimawi M, Wolff A, Tripathy D, Lin N, Stringer-Reasor E. Abstract PD4-02: Safety and efficacy of a tucatinib-trastuzumab-capecitabine regimen for treatment of leptomeningeal metastasis (LM) in HER2-positive breast cancer: Results from TBCRC049, a phase 2 non-randomized study Cancer Research 2022, 82: pd4-02-pd4-02. DOI: 10.1158/1538-7445.sabcs21-pd4-02.
  • Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033), a Phase II Randomized Trial of Adjuvant T-DM1 vs. TH in Women With Stage I HER2 Positive Breast CancerBellon J, Tayob N, Burstein H, Partridge A, Demeo M, Tralins J, Yang D, Dang C, Isakoff S, Yardley D, Valero V, Winer E, Krop I, Tolaney S. Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033), a Phase II Randomized Trial of Adjuvant T-DM1 vs. TH in Women With Stage I HER2 Positive Breast Cancer International Journal Of Radiation Oncology • Biology • Physics 2021, 111: s34. DOI: 10.1016/j.ijrobp.2021.07.103.
  • 259P Weekly ladiratuzumab vedotin monotherapy for metastatic triple-negative breast cancerTsai M, Han H, Montero A, Tkaczuk K, Assad H, Pusztai L, Hurvitz S, Wilks S, Specht J, Nanda R, Mita M, O'Shaughnessy J, Krop I, Medgyesy D, Abraham J, Modi S, Li H, Wu S, Garfin P, Burris H. 259P Weekly ladiratuzumab vedotin monotherapy for metastatic triple-negative breast cancer Annals Of Oncology 2021, 32: s474-s475. DOI: 10.1016/j.annonc.2021.08.542.
  • 120MO Prognostic value of immune gene-expression signatures (iGES) vs tumor-infiltrating lymphocytes (TILs) in early-stage HER2+ breast cancer: A combined analysis of CALGB 40601 (C40601) and PAMELA trialsFernandez-Martinez A, Pascual T, Singh B, Nuciforo P, Hoadley K, Rashid N, Spears P, Chic N, Krop I, Hillman D, Partridge A, Prat A, Carey L, Perou C. 120MO Prognostic value of immune gene-expression signatures (iGES) vs tumor-infiltrating lymphocytes (TILs) in early-stage HER2+ breast cancer: A combined analysis of CALGB 40601 (C40601) and PAMELA trials Annals Of Oncology 2021, 32: s409. DOI: 10.1016/j.annonc.2021.08.401.
  • 279P Trastuzumab deruxtecan (T-DXd) in patients with HER2-positive metastatic breast cancer (MBC): Updated survival results from a phase II trial (DESTINY-Breast01)Manich C, Modi S, Krop I, Park Y, Kim S, Tamura K, André F, Iwata H, Ito Y, Tsurutani J, Sohn J, Lee C, Liu Y, Cathcart J, Singh J, Yamashita T. 279P Trastuzumab deruxtecan (T-DXd) in patients with HER2-positive metastatic breast cancer (MBC): Updated survival results from a phase II trial (DESTINY-Breast01) Annals Of Oncology 2021, 32: s485-s486. DOI: 10.1016/j.annonc.2021.08.562.
  • 331TiP HER2CLIMB-04: Phase II trial of tucatinib + trastuzumab deruxtecan in patients with HER2+ locally advanced or metastatic breast cancer with and without brain metastasesCarey L, Krop I, Ramos J, Feng W, Hamilton E. 331TiP HER2CLIMB-04: Phase II trial of tucatinib + trastuzumab deruxtecan in patients with HER2+ locally advanced or metastatic breast cancer with and without brain metastases Annals Of Oncology 2021, 32: s510-s511. DOI: 10.1016/j.annonc.2021.08.614.
  • A phase I/Ib study evaluating GDC-0077 (inavolisib) + palbociclib (palbo) + fulvestrant in patients (pts) with PIK3CA -mutant (mut), hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2- mBC)Schmid P, Bedard P, Jhaveri K, Cervantes A, Gambardella V, Hamilton E, Italiano A, Kalinsky K, Krop I, Oliveira M, Saura C, Turner N, Varga A, Hutchinson K, Lei G, Royer-Joo S, Thomas P, JL S, Juric D. A phase I/Ib study evaluating GDC-0077 (inavolisib) + palbociclib (palbo) + fulvestrant in patients (pts) with PIK3CA -mutant (mut), hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2- mBC) Senologie - Zeitschrift Für Mammadiagnostik Und -therapie 2021, 18: e36-e37. DOI: 10.1055/s-0041-1730220.
  • Updated results of tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB).Curigliano G, Mueller V, Borges V, Hamilton E, Hurvitz S, Loi S, Murthy R, Okines A, Paplomata E, Cameron D, Carey L, Gelmon K, Hortobagyi G, Krop I, Loibl S, Pegram M, Slamon D, Ramos J, Zhang C, Winer E. Updated results of tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB). Journal Of Clinical Oncology 2021, 39: 1043-1043. DOI: 10.1200/jco.2021.39.15_suppl.1043.
  • Pharmacokinetic (PK) analyses in CSF and plasma from TBCRC049, an ongoing trial to assess the safety and efficacy of the combination of tucatinib, trastuzumab and capecitabine for the treatment of leptomeningeal metastasis (LM) in HER2 positive breast cancer.Stringer-Reasor E, O'Brien B, Topletz-Erickson A, White J, Lobbous M, Riley K, Childress J, LaMaster K, Melisko M, Morikawa A, De Groot J, Krop I, Valero V, Rimawi M, Wolff A, Tripathy D, Lin N, Murthy R. Pharmacokinetic (PK) analyses in CSF and plasma from TBCRC049, an ongoing trial to assess the safety and efficacy of the combination of tucatinib, trastuzumab and capecitabine for the treatment of leptomeningeal metastasis (LM) in HER2 positive breast cancer. Journal Of Clinical Oncology 2021, 39: 1044-1044. DOI: 10.1200/jco.2021.39.15_suppl.1044.
  • Trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer with brain metastases: A subgroup analysis of the DESTINY-Breast01 trial.Jerusalem G, Park Y, Yamashita T, Hurvitz S, Modi S, Andre F, Krop I, Gonzalez X, Hall P, You B, Saura C, Kim S, Osborne C, Sagara Y, Tokunaga E, Liu Y, Cathcart J, Lee C, Perrin C. Trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer with brain metastases: A subgroup analysis of the DESTINY-Breast01 trial. Journal Of Clinical Oncology 2021, 39: 526-526. DOI: 10.1200/jco.2021.39.15_suppl.526.
  • HER2CLIMB-04: Phase 2 open label trial of tucatinib plus trastuzumab deruxtecan in patients with HER2+ unresectable locally advanced or metastatic breast cancer with and without brain metastases (trial in progress).Krop I, Ramos J, Zhang C, Hamilton E. HER2CLIMB-04: Phase 2 open label trial of tucatinib plus trastuzumab deruxtecan in patients with HER2+ unresectable locally advanced or metastatic breast cancer with and without brain metastases (trial in progress). Journal Of Clinical Oncology 2021, 39: tps1097-tps1097. DOI: 10.1200/jco.2021.39.15_suppl.tps1097.
  • Trial in progress: A phase 1b/2 study of the PARP inhibitor niraparib in combination with trastuzumab in patients with metastatic HER2+ breast cancer (TBCRC 050).Stringer-Reasor E, Li Y, Witherspoon F, Specht J, Del Santo Anampa Mesias J, Nanda R, Dees E, Wolff A, Krop I, Lin N, Rimawi M, Yang E. Trial in progress: A phase 1b/2 study of the PARP inhibitor niraparib in combination with trastuzumab in patients with metastatic HER2+ breast cancer (TBCRC 050). Journal Of Clinical Oncology 2021, 39: tps1098-tps1098. DOI: 10.1200/jco.2021.39.15_suppl.tps1098.
  • A011801 (CompassHER2 RD): Postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer.O'Sullivan C, Ballman K, McCall L, Zemla T, Weiss A, Mitchell M, Blinder V, Tung N, Irvin W, Lee M, Goetz M, Symmans W, Borges V, Krop I, Partridge A, Carey L. A011801 (CompassHER2 RD): Postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer. Journal Of Clinical Oncology 2021, 39: tps595-tps595. DOI: 10.1200/jco.2021.39.15_suppl.tps595.
  • 42O Biomarker analysis from KAITLIN, a randomised phase III study of adjuvant trastuzumab emtansine (TDM-1; K) plus pertuzumab (P) versus trastuzumab (H) plus taxane (T) plus P after anthracyclines (AC) for high-risk HER2-positive early breast cancer (EBC)Metzger O, Lambertini C, Krop I, Phillips G, Perou C, Symmans F, Melero I, Harbeck N, Winer E, Im S, Barrios C, Bonnefoi H, Gralow J, Ellis P, Gianni L, Toi M, Swain S, Boulet T, Song C, de Haas S. 42O Biomarker analysis from KAITLIN, a randomised phase III study of adjuvant trastuzumab emtansine (TDM-1; K) plus pertuzumab (P) versus trastuzumab (H) plus taxane (T) plus P after anthracyclines (AC) for high-risk HER2-positive early breast cancer (EBC) Annals Of Oncology 2021, 32: s37-s38. DOI: 10.1016/j.annonc.2021.03.056.
  • LBA4 Datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate (ADC), for triple-negative breast cancer (TNBC): Preliminary results from an ongoing phase I trialBardia A, Juric D, Shimizu T, Tolcher A, Karim R, Spira A, Mukohara T, Lisberg A, Kogawa T, Krop I, Papadopoulos K, Hamilton E, Damodaran S, Greenberg J, Gu W, Kobayashi F, Guevara F, Jikoh T, Kawasaki Y, Meric-Bernstam F. LBA4 Datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate (ADC), for triple-negative breast cancer (TNBC): Preliminary results from an ongoing phase I trial Annals Of Oncology 2021, 32: s60. DOI: 10.1016/j.annonc.2021.03.213.
  • 128TiP HER2CLIMB-04: Phase II trial of tucatinib + trastuzumab deruxtecan in patients with HER2+ unresectable locally-advanced or metastatic breast cancer with and without brain metastasesHamilton E, Ramos J, Feng W, Krop I. 128TiP HER2CLIMB-04: Phase II trial of tucatinib + trastuzumab deruxtecan in patients with HER2+ unresectable locally-advanced or metastatic breast cancer with and without brain metastases Annals Of Oncology 2021, 32: s76. DOI: 10.1016/j.annonc.2021.03.142.
  • Abstract OT-03-06: Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized triple-negative breast cancer (NeoSTAR)Spring L, Tolaney S, Desai N, Comander A, Mulvey T, Krop I, Winer E, Mittendorf E, Ellisen L, Bardia A. Abstract OT-03-06: Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized triple-negative breast cancer (NeoSTAR) Cancer Research 2021, 81: ot-03-06-ot-03-06. DOI: 10.1158/1538-7445.sabcs20-ot-03-06.
  • Abstract PD3-05: The DAPHNE trial: A feasibility study of chemotherapy de-escalation based on response to neoadjuvant paclitaxel-HP (THP) in HER2-positive breast cancerWaks A, Desai N, Li T, Poorvu P, Partridge A, Sinclair N, Spring L, Faggen M, Constantine M, Alberti J, Deane J, Rosenberg S, Tolaney S, Krop I, Tung N, Tayob N, King T, Mittendorf E, Winer E. Abstract PD3-05: The DAPHNE trial: A feasibility study of chemotherapy de-escalation based on response to neoadjuvant paclitaxel-HP (THP) in HER2-positive breast cancer Cancer Research 2021, 81: pd3-05-pd3-05. DOI: 10.1158/1538-7445.sabcs20-pd3-05.
  • Abstract OT-03-03: SGNLVA-001: A phase 1 open-label dose escalation and expansion study of SGN-LIV1A administered weekly in breast cancerBeckwith H, Medgyesy D, Abraham J, Nanda R, Tkaczuk K, Krop I, Pusztai L, Modi S, Mita M, Specht J, Hurvitz S, Han H, Kalinsky K, Wilks S, O’Shaughnessy J, Hart L, Rugo H, Mitri Z, Garfin P, Burris H. Abstract OT-03-03: SGNLVA-001: A phase 1 open-label dose escalation and expansion study of SGN-LIV1A administered weekly in breast cancer Cancer Research 2021, 81: ot-03-03-ot-03-03. DOI: 10.1158/1538-7445.sabcs20-ot-03-03.
  • Abstract OT-28-03: VICKI: A Phase Ib/II, randomized, placebo-controlled, study of venetoclax plus ado-trastuzumab emtansine (T-DM1) in patients (pts) with previously treated HER2-positive locally advanced (LA) or metastatic breast cancer (MBC)Lindeman G, Hamilton E, Krop I, Lim B, Modi S, Saura C, Desai R, Danner B, Fernando T, Kong S, Legrand F, Nasroulah F. Abstract OT-28-03: VICKI: A Phase Ib/II, randomized, placebo-controlled, study of venetoclax plus ado-trastuzumab emtansine (T-DM1) in patients (pts) with previously treated HER2-positive locally advanced (LA) or metastatic breast cancer (MBC) Cancer Research 2021, 81: ot-28-03-ot-28-03. DOI: 10.1158/1538-7445.sabcs20-ot-28-03.
  • Abstract PD1-02: A phase I/Ib study evaluating GDC-0077 + palbociclib (palbo) + fulvestrant in patients (pts) with PIK3CA -mutant (mut), hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2- mBC)Bedard P, Jhaveri K, Cervantes A, Gambardella V, Hamilton E, Italiano A, Kalinsky K, Krop I, Oliveira M, Saura C, Schmid P, Turner N, Varga A, Hutchinson K, Lei G, Royer-Joo S, Thomas P, Schutzman J, Juric D. Abstract PD1-02: A phase I/Ib study evaluating GDC-0077 + palbociclib (palbo) + fulvestrant in patients (pts) with PIK3CA -mutant (mut), hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2- mBC) Cancer Research 2021, 81: pd1-02-pd1-02. DOI: 10.1158/1538-7445.sabcs20-pd1-02.
  • Abstract PD1-09: Safety and efficacy results from the phase 1/2 study of U3-1402, a human epidermal growth factor receptor 3 (HER3)-directed antibody drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC)Krop I, Yonemori K, Takahashi S, Inoue K, Nakayama T, Iwata H, Toyama T, Yamamoto Y, Takahashi M, Osaki A, Saji S, Sagara Y, O’Shaughnessy J, Traina T, Ohwada S, Qi Z, Qiu Y, Onuma H, Sharma O, Mekan S, Masuda N. Abstract PD1-09: Safety and efficacy results from the phase 1/2 study of U3-1402, a human epidermal growth factor receptor 3 (HER3)-directed antibody drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC) Cancer Research 2021, 81: pd1-09-pd1-09. DOI: 10.1158/1538-7445.sabcs20-pd1-09.
  • Abstract PD3-01: BluePrint performance in predicting pertuzumab benefit in genomically HER2-positive patients: A biomarker analysis of the APHINITY trialKrop I, Mittempergher L, Paulson J, Andre F, Bonnefoi H, Loi S, Loibl S, Gelber R, Caballero C, Fumagalli D, Dreezen C, Bernards R, van ‘t Veer L, Piccart M. Abstract PD3-01: BluePrint performance in predicting pertuzumab benefit in genomically HER2-positive patients: A biomarker analysis of the APHINITY trial Cancer Research 2021, 81: pd3-01-pd3-01. DOI: 10.1158/1538-7445.sabcs20-pd3-01.
  • Abstract PD3-06: Updated results from DESTINY-breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd ) in HER2 positive metastatic breast cancerModi S, Saura C, Yamashita T, Park Y, Kim S, Tamura K, Andre F, Iwata H, Ito Y, Tsurutani J, Sohn J, Denduluri N, Perrin C, Aogi K, Tokunaga E, Im S, Lee K, Hurvitz S, Cortes J, Lee C, Liu Y, Zhang L, Shahidi J, Yver A, Baselga J, Krop I. Abstract PD3-06: Updated results from DESTINY-breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd ) in HER2 positive metastatic breast cancer Cancer Research 2021, 81: pd3-06-pd3-06. DOI: 10.1158/1538-7445.sabcs20-pd3-06.
  • Abstract PD9-06: Peripheral blood gene signatures predict response to neoadjuvant chemotherapy in breast cancer patientsAxelrod M, Gonzalez-Ericsson P, Sun X, Bergman R, Donaldson J, Tolaney S, Krop I, Garrido-Castro A, Sanders M, Mayer I, Balko J. Abstract PD9-06: Peripheral blood gene signatures predict response to neoadjuvant chemotherapy in breast cancer patients Cancer Research 2021, 81: pd9-06-pd9-06. DOI: 10.1158/1538-7445.sabcs20-pd9-06.
  • Abstract PS10-01: 6-year absolute invasive disease-free survival (IDFS) benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A STEPP analysis of the APHINITY (BIG 4-11) trialGelber R, Wang X, Cole B, Cameron D, Cardoso F, Tjan-Heijnen V, Krop I, Loi S, Salgado R, Kiermaier A, Frank E, Fumagalli D, Caballero C, de Azambuja E, Procter M, Clark E, Restuccia E, Heeson S, Bines J, Loibl S, Piccart-Gebhardt M. Abstract PS10-01: 6-year absolute invasive disease-free survival (IDFS) benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A STEPP analysis of the APHINITY (BIG 4-11) trial Cancer Research 2021, 81: ps10-01-ps10-01. DOI: 10.1158/1538-7445.sabcs20-ps10-01.
  • Abstract PS11-11: Targeted safety events from a phase I/Ib study evaluating GDC-0077 alone and in combination with endocrine therapy (ET) ± palbociclib (palbo) in patients (pts) with PIK3CA -mutant (mut), hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2- mBC)Olivera M, Jhaveri K, Juric D, Bedard P, Cervantes A, Gambardella V, Hamilton E, Italiano A, Kalinsky K, Krop I, Schmid P, Turner N, Varga A, Lei G, Royer-Joo S, Thomas P, Schutzman J, Saura C. Abstract PS11-11: Targeted safety events from a phase I/Ib study evaluating GDC-0077 alone and in combination with endocrine therapy (ET) ± palbociclib (palbo) in patients (pts) with PIK3CA -mutant (mut), hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2- mBC) Cancer Research 2021, 81: ps11-11-ps11-11. DOI: 10.1158/1538-7445.sabcs20-ps11-11.
  • Abstract PS5-12: Preliminary correlative analysis of clinical outcomes with PIK3CA mutation (mut) status from a phase I/Ib study of GDC-0077 in patients (pts) with hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2- mBC)Jhaveri K, Juric D, Varga A, Turner N, Schmid P, Saura C, Oliveira M, Krop I, Kalinsky K, Italiano A, Hamilton E, Gambardella V, Cervantes A, Bedard P, Liu B, Chen J, Aimi J, Royer-Joo S, Schutzman J, Hutchinson K. Abstract PS5-12: Preliminary correlative analysis of clinical outcomes with PIK3CA mutation (mut) status from a phase I/Ib study of GDC-0077 in patients (pts) with hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2- mBC) Cancer Research 2021, 81: ps5-12-ps5-12. DOI: 10.1158/1538-7445.sabcs20-ps5-12.
  • CTNI-02. TBCRC049: A PHASE II STUDY TO ASSESS THE SAFETY AND EFFICACY OF THE COMBINATION OF TUCATINIB, TRASTUZUMAB AND CAPECITABINE FOR THE TREATMENT OF LEPTOMENINGEAL METASTASIS IN HER2 POSITIVE BR1AST CANCERMurthy R, O’Brien B, Berry D, Navin N, Johnson J, Gule-Monroe M, Leone J, Specht J, Melisko M, Morikawa A, Storniolo A, Brufsky A, Pohlmann P, Park D, Park B, Krop I, Lin N, Rimawi M, Wolff A, Forero-Torres A, Stringer-Reasor E. CTNI-02. TBCRC049: A PHASE II STUDY TO ASSESS THE SAFETY AND EFFICACY OF THE COMBINATION OF TUCATINIB, TRASTUZUMAB AND CAPECITABINE FOR THE TREATMENT OF LEPTOMENINGEAL METASTASIS IN HER2 POSITIVE BR1AST CANCER Neuro-Oncology 2020, 22: ii41-ii41. PMCID: PMC7650439, DOI: 10.1093/neuonc/noaa215.169.
  • PI3K pathway biomarkers and clinical response in a phase I/Ib study of GDC-0077 in hormone receptor-positive/HER2-negative breast cancer (HR+/HER2– BC)Gambardella V, Cervantes A, Bedard P, Hamilton E, Italiano A, Jhaveri K, Juric D, Kalinsky K, Krop I, Oliveira M, Saura C, Schmid P, Turner N, Varga A, Liu B, Chen J, Aimi J, Royer-Joo S, Schutzman J, Hutchinson K. PI3K pathway biomarkers and clinical response in a phase I/Ib study of GDC-0077 in hormone receptor-positive/HER2-negative breast cancer (HR+/HER2– BC) Annals Of Oncology 2020, 31: s381-s382. DOI: 10.1016/j.annonc.2020.08.438.
  • Abstract CT109: A phase I/Ib study evaluating GDC-0077 plus fulvestrant in patients with PIK3CA -mutant, hormone receptor-positive/HER2-negative breast cancerKalinsky K, Juric D, Bedard P, Oliveira M, Cervantes A, Hamilton E, Krop I, Turner N, Schmid P, Varga A, Italiano A, Veitch Z, Saura C, Gambardella V, Cheeti S, Kotani N, Lei G, Hutchinson K, Royer-Joo S, Vaze A, Schutzman J, Jhaveri K. Abstract CT109: A phase I/Ib study evaluating GDC-0077 plus fulvestrant in patients with PIK3CA -mutant, hormone receptor-positive/HER2-negative breast cancer Cancer Research 2020, 80: ct109-ct109. DOI: 10.1158/1538-7445.am2020-ct109.
  • Management of adverse events in patients with HER2+ metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabine (HER2CLIMB).Okines A, Paplomata E, Wahl T, Wright G, Sutherland S, Jakobsen E, Valdes F, Chan A, Clark A, Conlin A, Lustberg M, Specht J, Pluard T, Zhu X, Krop I, Gelmon K, Slamon D, Ramos J, An G, Hamilton E. Management of adverse events in patients with HER2+ metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabine (HER2CLIMB). Journal Of Clinical Oncology 2020, 38: 1043-1043. DOI: 10.1200/jco.2020.38.15_suppl.1043.
  • TBCRC 048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded).Tung N, Robson M, Ventz S, Santa-Maria C, Marcom P, Nanda R, Shah P, Ballinger T, Yang E, Melisko M, Brufsky A, Vinayak S, Demeo M, Jenkins C, Domchek S, Wulf G, Krop I, Wolff A, Winer E, Garber J. TBCRC 048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded). Journal Of Clinical Oncology 2020, 38: 1002-1002. DOI: 10.1200/jco.2020.38.15_suppl.1002.
  • A phase Ib study of pembrolizumab (pembro) plus trastuzumab emtansine (T-DM1) for metastatic HER2+ breast cancer (MBC).Waks A, Keenan T, Li T, Tayob N, Wulf G, Richardson E, Mittendorf E, Overmoyer B, Krop I, Winer E, Van Allen E, Agudo J, Tolaney S. A phase Ib study of pembrolizumab (pembro) plus trastuzumab emtansine (T-DM1) for metastatic HER2+ breast cancer (MBC). Journal Of Clinical Oncology 2020, 38: 1046-1046. DOI: 10.1200/jco.2020.38.15_suppl.1046.
  • Primary analysis of KAITLIN: A phase III study of trastuzumab emtansine (T-DM1) + pertuzumab versus trastuzumab + pertuzumab + taxane, after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer (EBC).Harbeck N, Im S, Barrios C, Bonnefoi H, Gralow J, Toi M, Ellis P, Gianni L, Swain S, Im Y, De Laurentiis M, Nowecki Z, Shah J, Boulet T, Liu H, Macharia H, Trask P, Song C, Winer E, Krop I. Primary analysis of KAITLIN: A phase III study of trastuzumab emtansine (T-DM1) + pertuzumab versus trastuzumab + pertuzumab + taxane, after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer (EBC). Journal Of Clinical Oncology 2020, 38: 500-500. DOI: 10.1200/jco.2020.38.15_suppl.500.
  • SGNLVA-001: A phase I open-label dose escalation and expansion study of SGN-LIV1A administered weekly in breast cancer.Beckwith H, Medgyesy D, Abraham J, Nanda R, Tkaczuk K, Krop I, Pusztai L, Modi S, Mita M, Specht J, Hurvitz S, Han H, Kalinsky K, Wilks S, O'Shaughnessy J, Hart L, Rugo H, Mitri Z, Garfin P, Burris III H. SGNLVA-001: A phase I open-label dose escalation and expansion study of SGN-LIV1A administered weekly in breast cancer. Journal Of Clinical Oncology 2020, 38: tps1104-tps1104. DOI: 10.1200/jco.2020.38.15_suppl.tps1104.
  • A multiparameter classifier to predict response to lapatinib plus trastuzumab (LT) without chemotherapy in HER2+ breast cancer (BC).Veeraraghavan J, Gutierrez C, De Angelis C, Wang T, Pascual T, Weigelt B, Galvan P, Rexer B, Forero-Torres A, Wolff A, Nanda R, Storniolo A, Krop I, Goetz M, Reis-Filho J, Hilsenbeck S, Prat A, Osborne C, Schiff R, Rimawi M. A multiparameter classifier to predict response to lapatinib plus trastuzumab (LT) without chemotherapy in HER2+ breast cancer (BC). Journal Of Clinical Oncology 2020, 38: 1011-1011. DOI: 10.1200/jco.2020.38.15_suppl.1011.
  • Trastuzumab deruxtecan for HER2-positive metastatic breast cancer: DESTINY-Breast01 subgroup analysis.Modi S, Andre F, Krop I, Saura C, Yamashita T, Kim S, Tamura K, Chen S, Suto F, Kuwahara Y, Lee C, Park Y. Trastuzumab deruxtecan for HER2-positive metastatic breast cancer: DESTINY-Breast01 subgroup analysis. Journal Of Clinical Oncology 2020, 38: 1036-1036. DOI: 10.1200/jco.2020.38.15_suppl.1036.
  • 3O Mutation analysis of circulating tumour DNA from baseline and study discontinuation samples in SANDPIPER, a phase III study of taselisib or placebo with fulvestrant in oestrogen receptor-positive, human epidermal growth factor receptor 2-negative, PIK3CA-mutant advanced breast cancerJacot W, Savage H, Dent S, Cortés J, Im Y, Dieras V, Harbeck N, Krop I, Chen J, Sokol E, Schimmoller F, Hsu J, De Laurentiis M, Wilson T. 3O Mutation analysis of circulating tumour DNA from baseline and study discontinuation samples in SANDPIPER, a phase III study of taselisib or placebo with fulvestrant in oestrogen receptor-positive, human epidermal growth factor receptor 2-negative, PIK3CA-mutant advanced breast cancer Annals Of Oncology 2020, 31: s16. DOI: 10.1016/j.annonc.2020.03.139.
  • Abstract GS6-03: Cisplatin versus doxorubicin/cyclophosphamide as neoadjuvant treatment in germline BRCA mutation carriers ( BRCA carriers) with HER2-negative breast cancer: Results from the INFORM trial (TBCRC 031)Tung N, Arun B, Hofstatter E, Hacker M, Toppmeyer D, Isakoff S, Borges V, Legare R, Isaacs C, Wolff A, Marcom P, Mayer E, Lange P, Goss A, Krop I, Winer E, Schnitt S, Garber J. Abstract GS6-03: Cisplatin versus doxorubicin/cyclophosphamide as neoadjuvant treatment in germline BRCA mutation carriers ( BRCA carriers) with HER2-negative breast cancer: Results from the INFORM trial (TBCRC 031) Cancer Research 2020, 80: gs6-03-gs6-03. DOI: 10.1158/1538-7445.sabcs19-gs6-03.
  • Abstract P2-13-02: Chemotherapy-related amenorrhea (CRA) after adjuvant trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT trial)Ruddy K, Trippa L, Hu J, Barry W, Dang C, Yardley D, Isakoff S, Valero V, Faggen M, Mulvey T, Bose R, Weckstein D, Wolff A, Reeder-Hayes K, Rugo H, Ramaswamy B, Zuckerman D, Hart L, Gadi V, Constantine M, Cheng K, Briccetti F, Schneider B, Garrett A, Marcom P, Albain K, DeFusco P, Tung N, Ardman B, Nanda R, Jankowitz R, DeMeo M, Burstein H, Winer E, Krop I, Partridge A, Tolaney S. Abstract P2-13-02: Chemotherapy-related amenorrhea (CRA) after adjuvant trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT trial) Cancer Research 2020, 80: p2-13-02-p2-13-02. DOI: 10.1158/1538-7445.sabcs19-p2-13-02.
  • Abstract P3-09-16: Fecal microbiome and association with outcomes among patients (pts) receiving eribulin (E) +/- pembrolizumab (P) for hormone receptor positive (HR+) metastatic breast cancer (MBC)de Sousa R, Ajami N, Keenan T, Andrews C, Pittenger J, Wulf G, Spring L, Krop I, Winer E, Mittendorf E, Tolaney S. Abstract P3-09-16: Fecal microbiome and association with outcomes among patients (pts) receiving eribulin (E) +/- pembrolizumab (P) for hormone receptor positive (HR+) metastatic breast cancer (MBC) Cancer Research 2020, 80: p3-09-16-p3-09-16. DOI: 10.1158/1538-7445.sabcs19-p3-09-16.
  • Abstract GS1-03: [Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) in subjects with HER2-positive metastatic breast cancer previously treated with T-DM1: A phase 2, multicenter, open-label study (DESTINY-Breast01)Krop I, Saura C, Yamashita T, Park Y, Kim S, Tamura K, André F, Iwata H, Ito Y, Tsurutani J, Sohn J, Denduluri N, Perrin C, Aogi K, Tokunaga E, Im S, Lee K, Hurvitz S, Cortes J, Lee C, Chen S, Zhang L, Shahidi J, Yver A, Modi S. Abstract GS1-03: [Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) in subjects with HER2-positive metastatic breast cancer previously treated with T-DM1: A phase 2, multicenter, open-label study (DESTINY-Breast01) Cancer Research 2020, 80: gs1-03-gs1-03. DOI: 10.1158/1538-7445.sabcs19-gs1-03.
  • Abstract OT1-07-04: [Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) vs investigator’s choice of treatment in subjects with HER2-positive, unresectable and/or metastatic breast cancer who previously received T-DM1: A randomized, phase 3 trial (DESTINY-Breast02)André F, Shahidi J, Lee C, Wang K, Krop I. Abstract OT1-07-04: [Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) vs investigator’s choice of treatment in subjects with HER2-positive, unresectable and/or metastatic breast cancer who previously received T-DM1: A randomized, phase 3 trial (DESTINY-Breast02) Cancer Research 2020, 80: ot1-07-04-ot1-07-04. DOI: 10.1158/1538-7445.sabcs19-ot1-07-04.
  • Abstract OT1-08-04: A first-in-human phase Ia dose escalation study of GDC-0077, a p110a-selective and mutant-degrading PI3K inhibitor, in patients with PIK3CA -mutant solid tumorsJuric D, Kalinsky K, Oliveira M, Cervantes A, Bedard P, Krop I, Hamilton E, Schmid P, Varga A, Turner N, Italiano A, Saura C, Gambardella V, Veitch Z, Dickmann L, Kotani N, Fredrickson J, Kapp A, Hutchinson K, Royer-Joo S, Vaze A, Schutzman J, Jhaveri K. Abstract OT1-08-04: A first-in-human phase Ia dose escalation study of GDC-0077, a p110a-selective and mutant-degrading PI3K inhibitor, in patients with PIK3CA -mutant solid tumors Cancer Research 2020, 80: ot1-08-04-ot1-08-04. DOI: 10.1158/1538-7445.sabcs19-ot1-08-04.
  • Abstract OT2-01-02: TBCRC049: A phase II non-randomized study to assess the safety and efficacy of the combination of tucatinib and trastuzumab and capecitabine for treatment of leptomeningeal metastases in HER2 positive breast cancer TBCRC049: A phase II non-randomized study to assess the safety and efficacy of the combination of tucatinib and trastuzumab and capecitabine for treatment of leptomeningeal metastases in HER2 positive breast cancerMurthy R, O'Brien B, Hess K, Navin N, Johnson J, Gule-Monroe M, Leone J, Specht J, Melisko M, Morikawa A, Storniolo A, Brufsky A, Pohlmann P, Park D, Park B, Krop I, Lin N, Wolff A, Forerro-Torres A, Stringer-Reasor E. Abstract OT2-01-02: TBCRC049: A phase II non-randomized study to assess the safety and efficacy of the combination of tucatinib and trastuzumab and capecitabine for treatment of leptomeningeal metastases in HER2 positive breast cancer TBCRC049: A phase II non-randomized study to assess the safety and efficacy of the combination of tucatinib and trastuzumab and capecitabine for treatment of leptomeningeal metastases in HER2 positive breast cancer Cancer Research 2020, 80: ot2-01-02-ot2-01-02. DOI: 10.1158/1538-7445.sabcs19-ot2-01-02.
  • Abstract OT2-07-01: A phase 2 study of futibatinib (TAS-120) in metastatic breast cancers harboring fibroblast growth factor receptor ( FGFR ) amplifications (FOENIX-MBC2)Turner N, Krop I, Bardia A, Damodaran S, Martin M, Benhadji K, He Y, Ptaszynski M, Arteaga C. Abstract OT2-07-01: A phase 2 study of futibatinib (TAS-120) in metastatic breast cancers harboring fibroblast growth factor receptor ( FGFR ) amplifications (FOENIX-MBC2) Cancer Research 2020, 80: ot2-07-01-ot2-07-01. DOI: 10.1158/1538-7445.sabcs19-ot2-07-01.
  • Abstract P1-19-46: A phase Ib dose escalation study evaluating the mutant selective PI3K-alpha inhibitor GDC-0077 (G) in combination with letrozole (L) with and without palbociclib (P) in patients with PIK3CA -mutant HR+/HER2- breast cancerJhaveri K, Kalinsky K, Bedard P, Cervantes A, Saura C, Krop I, Hamilton E, Schmid P, Varga A, Turner N, Italiano A, Gambardella V, Veitch Z, Oliveira M, Dickmann L, Kotani N, Kapp A, Hutchinson K, Royer-Joo S, Vaze A, Schutzman J, Juric D. Abstract P1-19-46: A phase Ib dose escalation study evaluating the mutant selective PI3K-alpha inhibitor GDC-0077 (G) in combination with letrozole (L) with and without palbociclib (P) in patients with PIK3CA -mutant HR+/HER2- breast cancer Cancer Research 2020, 80: p1-19-46-p1-19-46. DOI: 10.1158/1538-7445.sabcs19-p1-19-46.
  • Abstract P5-01-03: Ultrasensitive detection of minimal residual disease in patients treated for breast cancerParsons H, Rhoades J, Reed S, Gydush G, Ram P, Exman P, Xiong K, Lo C, Li T, Fleharty M, Kirkner G, Rotem D, Cohen O, Hughes M, Rosenberg S, Collins L, Miller K, Blumenstiel B, Cibulskis C, Neuberg D, Freeman S, Lennon N, Wagle N, Ha G, Stover D, Choudhury A, Getz G, Meyerson M, Lin N, Krop I, Love J, Makrigiorgos G, Partridge A, Mayer E, Golub T, Adalsteinsson V. Abstract P5-01-03: Ultrasensitive detection of minimal residual disease in patients treated for breast cancer Cancer Research 2020, 80: p5-01-03-p5-01-03. DOI: 10.1158/1538-7445.sabcs19-p5-01-03.
  • 174O Predictive and prognostic value of B-cell gene-expression signatures and B-cell receptor (BCR) repertoire in HER2+ breast cancer: A correlative analysis of the CALGB 40601 clinical trial (Alliance)Fernandez-Martinez A, Tanioka M, Fan C, Parker J, Hoadley K, Krop I, Partridge A, Carey L, Perou C. 174O Predictive and prognostic value of B-cell gene-expression signatures and B-cell receptor (BCR) repertoire in HER2+ breast cancer: A correlative analysis of the CALGB 40601 clinical trial (Alliance) Annals Of Oncology 2019, 30: v55. DOI: 10.1093/annonc/mdz240.
  • O1-8-4 [Encore] Dose justification for [fam-] trastuzumab deruxtecan (DS-8201a) in HER2-positive breast cancerTakahashi S, Modi S, Tsurutani J, Krop I, Iwata H, Wada R, Yin O, Garimella T, Sugihara M, Zhang L, Lee C, Saito K, Kawasaki Y, Yver A, Tamura K. O1-8-4 [Encore] Dose justification for [fam-] trastuzumab deruxtecan (DS-8201a) in HER2-positive breast cancer Annals Of Oncology 2019, 30: vi84. DOI: 10.1093/annonc/mdz339.009.
  • Abstract CT015: Phase I dose-escalation study of the allosteric AKT inhibitor BAY 1125976 in advanced solid cancerSchneeweiss A, Hess D, Joerger M, Varga A, Moulder S, Ma C, Krop I, Hurvitz S, Rentzsch C, Rudolph M, Boix O, Wilkinson G, Lindbom L, Lagkadinou E, Ocker M. Abstract CT015: Phase I dose-escalation study of the allosteric AKT inhibitor BAY 1125976 in advanced solid cancer 2019, ct015-ct015. DOI: 10.1158/1538-7445.sabcs18-ct015.
  • Abstract CT015: Phase I dose-escalation study of the allosteric AKT inhibitor BAY 1125976 in advanced solid cancerSchneeweiss A, Hess D, Joerger M, Varga A, Moulder S, Ma C, Krop I, Hurvitz S, Rentzsch C, Rudolph M, Boix O, Wilkinson G, Lindbom L, Lagkadinou E, Ocker M. Abstract CT015: Phase I dose-escalation study of the allosteric AKT inhibitor BAY 1125976 in advanced solid cancer Cancer Research 2019, 79: ct015-ct015. DOI: 10.1158/1538-7445.am2019-ct015.
  • Randomized phase II study of eribulin mesylate (E) with or without pembrolizumab (P) for hormone receptor-positive (HR+) metastatic breast cancer (MBC).Tolaney S, Barroso-Sousa R, Keenan T, Trippa L, Hu J, Luis I, Wulf G, Spring L, Sinclair N, Andrews C, Pittenger J, Richardson E, Dillon D, Lin N, Overmoyer B, Partridge A, VanAllen E, Mittendorf E, Winer E, Krop I. Randomized phase II study of eribulin mesylate (E) with or without pembrolizumab (P) for hormone receptor-positive (HR+) metastatic breast cancer (MBC). Journal Of Clinical Oncology 2019, 37: 1004-1004. DOI: 10.1200/jco.2019.37.15_suppl.1004.
  • Genomic landscape of de novo stage IV breast cancer.Garrido-Castro A, Spurr L, Hughes M, Li Y, Cherniack A, Bychkovsky B, Barroso-Sousa R, Di Lascio S, Files J, Kumari P, Cerami E, Krop I, MacConaill L, Lindeman N, Rollins B, Johnson B, Wagle N, Winer E, Dillon D, Lin N. Genomic landscape of de novo stage IV breast cancer. Journal Of Clinical Oncology 2019, 37: 1022-1022. DOI: 10.1200/jco.2019.37.15_suppl.1022.
  • A phase II study of pembrolizumab in combination with palliative radiotherapy (RT) for hormone receptor-positive (HR+) metastatic breast cancer (MBC).Barroso-Sousa R, Krop I, Trippa L, Tan-Wasielewski Z, Li T, Osmani W, Andrews C, Dillon D, Richardson E, Winer E, Mittendorf E, Schoenfeld J, Tolaney S. A phase II study of pembrolizumab in combination with palliative radiotherapy (RT) for hormone receptor-positive (HR+) metastatic breast cancer (MBC). Journal Of Clinical Oncology 2019, 37: 1047-1047. DOI: 10.1200/jco.2019.37.15_suppl.1047.
  • Reversion and non-reversion mechanisms of resistance (MoR) to PARP inhibitor (PARPi) or platinum chemotherapy (chemotx) in patients (pts) with BRCA1/2 -mutant metastatic breast cancer (MBC).Waks A, Cohen O, Kochupurakkal B, Kim D, Wander S, Buendia-Buendia J, Helvie K, Matulonis U, Krop I, Tolaney S, Winer E, D'Andrea A, Shapiro G, Lin N, Wagle N. Reversion and non-reversion mechanisms of resistance (MoR) to PARP inhibitor (PARPi) or platinum chemotherapy (chemotx) in patients (pts) with BRCA1/2 -mutant metastatic breast cancer (MBC). Journal Of Clinical Oncology 2019, 37: 1085-1085. DOI: 10.1200/jco.2019.37.15_suppl.1085.
  • HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: Results from a prospective clinical trial.Metzger Filho O, Viale G, Trippa L, Li T, Yardley D, Mayer I, Abramson V, Arteaga C, Spring L, Waks A, Janiszewska M, Wrabel E, Demeo M, Bardia A, King T, Polyak K, Winer E, Krop I. HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: Results from a prospective clinical trial. Journal Of Clinical Oncology 2019, 37: 502-502. DOI: 10.1200/jco.2019.37.15_suppl.502.
  • Genomic correlates of response to adjuvant trastuzumab (H) and pertuzumab (P) in HER2+ breast cancer (BC): Biomarker analysis of the APHINITY trial.Krop I, Paulson J, Campbell C, Kiermaier A, Andre F, Fumagalli D, de Haas S, Salgado R, Denkert C, Loibl S, Bailey A, Lewis Phillips G, Frank E, Piccart M, Viale G, Loi S. Genomic correlates of response to adjuvant trastuzumab (H) and pertuzumab (P) in HER2+ breast cancer (BC): Biomarker analysis of the APHINITY trial. Journal Of Clinical Oncology 2019, 37: 1012-1012. DOI: 10.1200/jco.2019.37.15_suppl.1012.
  • Genomic-based predictive biomarkers to anti-HER2 therapies: A combined analysis of CALGB 40601 (Alliance) and PAMELA clinical trials.Fernandez-Martinez A, Tanioka M, Fan C, Parker J, Hoadley K, Krop I, Cortes J, Llombart Cussac A, Nuciforo P, Galván P, Pascual T, Partridge A, Prat A, Carey L, Perou C. Genomic-based predictive biomarkers to anti-HER2 therapies: A combined analysis of CALGB 40601 (Alliance) and PAMELA clinical trials. Journal Of Clinical Oncology 2019, 37: 571-571. DOI: 10.1200/jco.2019.37.15_suppl.571.
  • 197TiP Phase III study of [fam-] trastuzumab deruxtecan vs investigator’s choice in T-DM1-pretreated HER2+ breast cancerAndré F, Shahidi J, Lee C, Wang K, Krop I. 197TiP Phase III study of [fam-] trastuzumab deruxtecan vs investigator’s choice in T-DM1-pretreated HER2+ breast cancer Annals Of Oncology 2019, 30: iii63. DOI: 10.1093/annonc/mdz100.048.
  • Abstract OT3-02-07: PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC)Metzger O, Mandrekar S, Loibl S, Mundhenke C, Seiler S, Valagussa P, Lim E, Tripathy D, Winer E, Huang C, Carey L, Francis P, Miller K, Goetz M, Prat A, Loi S, Krop I, Gianni L, Delalogue S, Vaz-Luis I, Dockter T, Lanzillotti J, Ciruelos E, DeMichele A. Abstract OT3-02-07: PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC) Cancer Research 2019, 79: ot3-02-07-ot3-02-07. DOI: 10.1158/1538-7445.sabcs18-ot3-02-07.
  • Abstract P1-15-01: WithdrawnMetzger Filho O, Janiszewska M, Guo H, Yardley D, Mayer I, Spring L, Arteaga C, Wrabel E, DeMeo M, Freedman R, Tolaney S, Waks A, Bardia A, Parsons H, Partridge A, Mayer E, King T, Polyak K, Viale G, Winer E, Krop I. Abstract P1-15-01: Withdrawn Cancer Research 2019, 79: p1-15-01-p1-15-01. DOI: 10.1158/1538-7445.sabcs18-p1-15-01.
  • Abstract P3-08-04: Transient state change, but not permanent subtype change, after HER2-targeted therapy for HER2-positive breast cancerTanioka M, Parker J, Henry L, Tolaney S, Dang C, Krop I, Harris L, Polley M, Berry D, Winer E, Carey L, Perou C. Abstract P3-08-04: Transient state change, but not permanent subtype change, after HER2-targeted therapy for HER2-positive breast cancer Cancer Research 2019, 79: p3-08-04-p3-08-04. DOI: 10.1158/1538-7445.sabcs18-p3-08-04.
  • Abstract P4-04-02: Identifying ERBB-2 activating mutations (mts) in HER2 negative tumors for clinical trials – Impact of institute-wide genomic testing and trial matching on trial enrollment in clinical practiceExman P, Garrido-Castro A, Hughes M, Freedman R, Ma C, Bose R, Cerami E, Wagle N, Barroso-Sousa R, Fitz C, Lindeman N, MacConaill L, Bychkovsky B, Lloyd M, Mackichan C, Kumari P, Tolaney S, Krop I, Winer E, Dillon D, Lin N. Abstract P4-04-02: Identifying ERBB-2 activating mutations (mts) in HER2 negative tumors for clinical trials – Impact of institute-wide genomic testing and trial matching on trial enrollment in clinical practice Cancer Research 2019, 79: p4-04-02-p4-04-02. DOI: 10.1158/1538-7445.sabcs18-p4-04-02.
  • Abstract P5-12-02: PTEN alterations and tumor mutational burden (TMB) as potential predictors of resistance or response to immune checkpoint inhibitors (ICI) in metastatic triple-negative breast cancer (mTNBC)Barroso-Sousa R, Tyekucheva S, Pernas-Simon S, Exman P, Jain E, Garrido-Castro A, Hughes M, Bychkovsky B, Di Lascio S, Umeton R, Files J, Lindeman N, MacConaill L, Hodi F, Krop I, Dillon D, Winer E, Wagle N, Lin N, Mittendorf E, Tolaney S. Abstract P5-12-02: PTEN alterations and tumor mutational burden (TMB) as potential predictors of resistance or response to immune checkpoint inhibitors (ICI) in metastatic triple-negative breast cancer (mTNBC) Cancer Research 2019, 79: p5-12-02-p5-12-02. DOI: 10.1158/1538-7445.sabcs18-p5-12-02.
  • Abstract PD1-05: Results from the phase Ib/II clinical trial of bazedoxifene and palbociclib in hormone receptor positive metastatic breast cancerJeselsohn R, Guo H, Rees R, Barry W, Barlett C, Tung N, Krop I, Brown M, Winer E. Abstract PD1-05: Results from the phase Ib/II clinical trial of bazedoxifene and palbociclib in hormone receptor positive metastatic breast cancer Cancer Research 2019, 79: pd1-05-pd1-05. DOI: 10.1158/1538-7445.sabcs18-pd1-05.
  • Abstract PD9-01: Genomic alterations associated with loss of HR expression in metastatic breast cancerGarrido-Castro A, Hughes M, Cherniack A, Barroso-Sousa R, Bychkovsky B, Di Lascio S, Berger A, Mittendorf E, Files J, Guo H, Kumari P, Cerami E, Krop I, Wagle N, Lindeman N, MacConaill L, Dillon D, Winer E, Lin N. Abstract PD9-01: Genomic alterations associated with loss of HR expression in metastatic breast cancer Cancer Research 2019, 79: pd9-01-pd9-01. DOI: 10.1158/1538-7445.sabcs18-pd9-01.
  • Abstract OT2-07-02: Trastuzumab deruxtecan (DS-8201a) vs investigator's choice of treatment in subjects with HER2-positive, unresectable and/or metastatic breast cancer who previously received T-DM1: A randomized, phase 3 studyAndré F, Shahidi J, Lee C, Wang K, Krop I. Abstract OT2-07-02: Trastuzumab deruxtecan (DS-8201a) vs investigator's choice of treatment in subjects with HER2-positive, unresectable and/or metastatic breast cancer who previously received T-DM1: A randomized, phase 3 study Cancer Research 2019, 79: ot2-07-02-ot2-07-02. DOI: 10.1158/1538-7445.sabcs18-ot2-07-02.
  • Abstract P6-17-02: Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-low expressing breast cancer: Updated results of a large phase 1 studyModi S, Tsurutani J, Tamura K, Park H, Sagara Y, Murthy R, Iwata H, Krop I, Doi T, Redfern C, Moreno-Aspitia A, Redman R, Lee C, Sugihara M, Fujisaki Y, Takahashi S. Abstract P6-17-02: Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-low expressing breast cancer: Updated results of a large phase 1 study Cancer Research 2019, 79: p6-17-02-p6-17-02. DOI: 10.1158/1538-7445.sabcs18-p6-17-02.
  • Abstract P6-17-06: Characterization, monitoring and management of interstitial lung disease in patients with metastatic breast cancer: Analysis of data available from multiple studies of DS-8201a, a HER2-targeted antibody drug conjugate with a topoisomerase I inhibitor payloadPowell C, Camidge D, Gemma A, Kusumoto M, Baba T, Kuwano K, Bankier A, Kiura K, Tamura K, Modi S, Tsurutani J, Doi T, Iwata H, Krop I, Zhang L, Jasmeet S, Saito K, Shahidi J, Yver A, Takahashi S. Abstract P6-17-06: Characterization, monitoring and management of interstitial lung disease in patients with metastatic breast cancer: Analysis of data available from multiple studies of DS-8201a, a HER2-targeted antibody drug conjugate with a topoisomerase I inhibitor payload Cancer Research 2019, 79: p6-17-06-p6-17-06. DOI: 10.1158/1538-7445.sabcs18-p6-17-06.
  • Abstract P6-17-10: Dose justification for DS-8201a, a HER2-targeted antibody-drug conjugate, for HER2-positive breast cancer: Observed clinical data and exposure-response analysesTamura K, Modi S, Tsurutani J, Takahashi S, Krop I, Iwata H, Wada R, Yin O, Garimella T, Sugihara M, Zhang L, Lee C, Yver A, Baselga J. Abstract P6-17-10: Dose justification for DS-8201a, a HER2-targeted antibody-drug conjugate, for HER2-positive breast cancer: Observed clinical data and exposure-response analyses Cancer Research 2019, 79: p6-17-10-p6-17-10. DOI: 10.1158/1538-7445.sabcs18-p6-17-10.
  • SPS-3 A prognostic model integrating clinical data and gene signatures in phase III neoadjuvant trial CALGB 40601 (Alliance)Tanioka M, Parker J, Henry L, Tolaney S, Dang C, Krop I, Harris L, Hillman D, Polley M, Berry D, Winer E, Carey L, Perou C. SPS-3 A prognostic model integrating clinical data and gene signatures in phase III neoadjuvant trial CALGB 40601 (Alliance) Annals Of Oncology 2018, 29: vii50. DOI: 10.1093/annonc/mdy373.
  • 369TiP PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + Anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC)Loibl S, Metzger O, Mandrekar S, Mundhenke C, Seiler S, Valagussa P, DeMichele A, Lim E, Tripathy D, Winer E, Huang C, Carey L, Francis P, Miller K, Goetz M, Prat A, Loi S, Krop I, Gianni L, Ciruelos E. 369TiP PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + Anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC) Annals Of Oncology 2018, 29: viii121. DOI: 10.1093/annonc/mdy272.357.
  • 286PD Post-treatment biopsies show evidence of cell cycle arrest and immune cell infiltration into tumors of ladiratuzumab vedotin-treated advanced breast cancer patientsSpecht J, Pusztai L, Forero-Torres A, Mita M, Weise A, Krop I, Grosse-Wilde A, Wang Z, Li M, Hengel S, Garfin P, Means G, Onsum M, Modi S. 286PD Post-treatment biopsies show evidence of cell cycle arrest and immune cell infiltration into tumors of ladiratuzumab vedotin-treated advanced breast cancer patients Annals Of Oncology 2018, 29: viii92. DOI: 10.1093/annonc/mdy272.278.
  • OA02.07 Updated Results of Phase 1 Study of DS-8201a in HER2-Expressing or –Mutated Advanced Non-Small-Cell Lung CancerTsurutani J, Park H, Doi T, Modi S, Takahashi S, Nakagawa K, Krop I, Waqar S, Yoh K, Li B, Taira S, Jikoh T, Singh J, Sugihara M, Jänne P. OA02.07 Updated Results of Phase 1 Study of DS-8201a in HER2-Expressing or –Mutated Advanced Non-Small-Cell Lung Cancer Journal Of Thoracic Oncology 2018, 13: s324. DOI: 10.1016/j.jtho.2018.08.244.
  • Abstract B04: CDK4/6 inhibition triggers an antitumor immune responseDeCristo M, Goel S, Watt A, BrinJones H, Sceneay J, Li B, Khan N, Ubellacker J, Xie S, Metzger-Filho O, Hoog J, Ellis M, Ma C, Ramm S, Krop I, Winer E, Roberts T, Kim H, Zhao J, McAllister S. Abstract B04: CDK4/6 inhibition triggers an antitumor immune response Cancer Immunology Research 2018, 6: b04-b04. DOI: 10.1158/2326-6074.tumimm17-b04.
  • Abstract 4564: The immune microenvironment in hormone receptor-positive breast cancer and treatment outcome following preoperative chemotherapy plus bevacizumabWaks A, Stover D, Barry W, Dillon D, Gjini E, Rodig S, Brock J, Baltay M, Savoie J, Winer E, Krop I, Tolaney S. Abstract 4564: The immune microenvironment in hormone receptor-positive breast cancer and treatment outcome following preoperative chemotherapy plus bevacizumab Cancer Research 2018, 78: 4564-4564. DOI: 10.1158/1538-7445.am2018-4564.
  • Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA -mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.Baselga J, Dent S, Cortés J, Im Y, Diéras V, Harbeck N, Krop I, Verma S, Wilson T, Jin H, Wang L, Schimmoller F, Hsu J, He J, DeLaurentiis M, Drullinsky P, Jacot W. Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA -mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER. Journal Of Clinical Oncology 2018, 36: lba1006-lba1006. DOI: 10.1200/jco.2018.36.18_suppl.lba1006.
  • The tumor-immune microenvironment (TME) in HR+/HER2- metastatic breast cancer (mBC): Relationship to non-metastatic (met) tumors and prior treatment (tx) received.Waks A, Tolaney S, Schnitt S, Dillon D, Gjini E, Abdelrahman S, Marino-Enriquez A, Helvie K, Marini L, Cohen O, Kim D, Wander S, Stover D, Rodig S, Krop I, Winer E, Lin N, Wagle N. The tumor-immune microenvironment (TME) in HR+/HER2- metastatic breast cancer (mBC): Relationship to non-metastatic (met) tumors and prior treatment (tx) received. Journal Of Clinical Oncology 2018, 36: 1054-1054. DOI: 10.1200/jco.2018.36.15_suppl.1054.
  • A phase II study of atezolizumab (Atezo) combined with pertuzumab (P) and high-dose trastuzumab (H) for the treatment of central nervous system (CNS) metastases in patients with Her2-positive (HER2+) metastatic breast cancer (MBC).Barroso-Sousa R, Barry W, Kumthekar P, Guo H, Silvestri K, Krop I, Winer E, Tolaney S, Lin N. A phase II study of atezolizumab (Atezo) combined with pertuzumab (P) and high-dose trastuzumab (H) for the treatment of central nervous system (CNS) metastases in patients with Her2-positive (HER2+) metastatic breast cancer (MBC). Journal Of Clinical Oncology 2018, 36: tps1100-tps1100. DOI: 10.1200/jco.2018.36.15_suppl.tps1100.
  • A randomized phase II trial of carboplatin with or without nivolumab in first- or second-line metastatic TNBC.Garrido-Castro A, Barry W, Traina T, Wesolowski R, Tung N, Keenan T, Van Allen E, Lin N, Winer E, Krop I, Tolaney S. A randomized phase II trial of carboplatin with or without nivolumab in first- or second-line metastatic TNBC. Journal Of Clinical Oncology 2018, 36: tps1118-tps1118. DOI: 10.1200/jco.2018.36.15_suppl.tps1118.
  • Results from molecular analysis for therapy choice (MATCH) arm I: Taselisib for PIK3CA-mutated tumors.Krop I, Jegede O, Grilley-Olson J, Lauring J, Hamilton S, Zwiebel J, Li S, Rubinstein L, Doyle A, Patton D, Mitchell E, Arteaga C, Conley B, Sims D, Harris L, Chen A, Flaherty K. Results from molecular analysis for therapy choice (MATCH) arm I: Taselisib for PIK3CA-mutated tumors. Journal Of Clinical Oncology 2018, 36: 101-101. DOI: 10.1200/jco.2018.36.15_suppl.101.
  • Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing solid tumors: Long-term results of a large phase 1 study with multiple expansion cohorts.Iwata H, Tamura K, Doi T, Tsurutani J, Modi S, Park H, Krop I, Sagara Y, Redfern C, Murthy R, Redman R, Shitara K, Fujisaki Y, Sugihara M, Zhang L, Shahidi J, Yver A, Takahashi S. Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing solid tumors: Long-term results of a large phase 1 study with multiple expansion cohorts. Journal Of Clinical Oncology 2018, 36: 2501-2501. DOI: 10.1200/jco.2018.36.15_suppl.2501.
  • HER2-enriched subtype and ERBB2 mRNA as predictors of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer: A combined analysis of TBCRC006/023 and PAMELA trials.Prat A, De Angelis C, Pascual T, Gutierrez C, Llombart-Cussac A, Wang T, Cortes J, Rexer B, Veeraraghavan J, Forero-Torres A, Wolff A, Morales S, Krop I, Pavlick A, Bermejo B, Hilsenbeck S, Oliveira M, Schiff R, Osborne C, Rimawi M. HER2-enriched subtype and ERBB2 mRNA as predictors of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer: A combined analysis of TBCRC006/023 and PAMELA trials. Journal Of Clinical Oncology 2018, 36: 509-509. DOI: 10.1200/jco.2018.36.15_suppl.509.
  • Abstract GS3-02: Invasive disease-free survival and gene expression signatures in CALGB (Alliance) 40601, a randomized phase III neoadjuvant trial of dual HER2-targeting with lapatinib added to chemotherapy plus trastuzumabKrop I, Hillman D, Polley M, Tanioka M, Parker J, Huebner L, Henry N, Tolaney S, Dang C, Harris L, Berry D, Perou C, Partridge A, Winer E, Carey L. Abstract GS3-02: Invasive disease-free survival and gene expression signatures in CALGB (Alliance) 40601, a randomized phase III neoadjuvant trial of dual HER2-targeting with lapatinib added to chemotherapy plus trastuzumab Cancer Research 2018, 78: gs3-02-gs3-02. DOI: 10.1158/1538-7445.sabcs17-gs3-02.
  • Abstract GS3-07: Genome-wide copy number analysis of chemotherapy-resistant metastatic triple-negative breast cancer from cell-free DNAStover D, Parsons H, Ha G, Freeman S, Barry B, Guo H, Choudhury A, Gydush G, Reed S, Rhoades J, Rotem D, Hughes M, Dillon D, Partridge A, Wagle N, Krop I, Getz G, Golub T, Love J, Winer E, Tolaney S, Lin N, Adalsteinsson V. Abstract GS3-07: Genome-wide copy number analysis of chemotherapy-resistant metastatic triple-negative breast cancer from cell-free DNA Cancer Research 2018, 78: gs3-07-gs3-07. DOI: 10.1158/1538-7445.sabcs17-gs3-07.
  • Abstract GS4-07: Results from a randomized placebo-controlled phase 2 trial evaluating exemestane ± enzalutamide in patients with hormone receptor–positive breast cancerKrop I, Abramson V, Colleoni M, Traina T, Holmes F, Estevez L, Hart L, Awada A, Zamagni C, Morris P, Schwartzberg L, Chan S, Wheatley D, Gucalp A, Biganzoli L, Steinberg J, Gianni L, Trudeau M, Tudor I, Markova D, Barry E, Tarazi J, Stewart R, Winer E, Yardley D. Abstract GS4-07: Results from a randomized placebo-controlled phase 2 trial evaluating exemestane ± enzalutamide in patients with hormone receptor–positive breast cancer Cancer Research 2018, 78: gs4-07-gs4-07. DOI: 10.1158/1538-7445.sabcs17-gs4-07.
  • Abstract OT3-05-07: PATINA: A randomized open label phase III trial to evaluate the efficacy and safety of palbociclib + anti HER2 therapy + endocrine therapy vs anti HER2 therapy + endocrine therapy after induction treatment for hormone receptor positive, HER2 positive metastatic breast cancerMetzger-Filho O, Mandrekar S, Loibl S, Ciruelos E, Gianni L, Lim E, Miller K, Huang C, Koehler M, Francis P, Valagussa P, Goel S, Prat A, Goetz M, Loi S, Krop I, Carey L, Lanzillotti J, Winer E, Tripathy D, DeMichele A. Abstract OT3-05-07: PATINA: A randomized open label phase III trial to evaluate the efficacy and safety of palbociclib + anti HER2 therapy + endocrine therapy vs anti HER2 therapy + endocrine therapy after induction treatment for hormone receptor positive, HER2 positive metastatic breast cancer Cancer Research 2018, 78: ot3-05-07-ot3-05-07. DOI: 10.1158/1538-7445.sabcs17-ot3-05-07.
  • Abstract PD3-01: Immune profile of small HER2+ tumors in the APT trialTolaney S, Barry W, Guo H, Dillon D, Tan Y, Fuhrman K, Osmani W, Getz A, Baltay M, Dang C, Yardley D, Moy B, Marcom K, Krop I, Winer E. Abstract PD3-01: Immune profile of small HER2+ tumors in the APT trial Cancer Research 2018, 78: pd3-01-pd3-01. DOI: 10.1158/1538-7445.sabcs17-pd3-01.
  • Abstract PD6-09: The immune microenvironment in hormone receptor-positive breast cancer patients and relationship to treatment outcome following preoperative chemotherapy plus bevacizumabWaks A, Stover D, Barry W, Dillon D, Gjini E, Rodig S, Brock J, Baltay M, Savoie J, Winer E, Krop I, Tolaney S. Abstract PD6-09: The immune microenvironment in hormone receptor-positive breast cancer patients and relationship to treatment outcome following preoperative chemotherapy plus bevacizumab Cancer Research 2018, 78: pd6-09-pd6-09. DOI: 10.1158/1538-7445.sabcs17-pd6-09.
  • Abstract PD3-14: Phase 1 study of the antibody-drug conjugate SGN-LIV1A in patients with heavily pretreated triple-negative metastatic breast cancerModi S, Pusztai L, Forero A, Mita M, Miller K, Weise A, Krop I, Burris H, Kalinsky K, Tsai M, Liu M, Hurvitz S, Wilks S, Ademuyiwa F, Diab S, Han H, Kato G, Nanda R, O'Shaughnessy J, Kostic A, Li M, Specht J. Abstract PD3-14: Phase 1 study of the antibody-drug conjugate SGN-LIV1A in patients with heavily pretreated triple-negative metastatic breast cancer Cancer Research 2018, 78: pd3-14-pd3-14. DOI: 10.1158/1538-7445.sabcs17-pd3-14.
  • Abstract OT1-02-02: A phase II study of pembrolizumab in combination with palliative radiotherapy for metastatic hormone receptor positive breast cancerBarroso-Sousa R, Gao H, Barry W, Krop I, Schoenfeld J, Tolaney S. Abstract OT1-02-02: A phase II study of pembrolizumab in combination with palliative radiotherapy for metastatic hormone receptor positive breast cancer Cancer Research 2018, 78: ot1-02-02-ot1-02-02. DOI: 10.1158/1538-7445.sabcs17-ot1-02-02.
  • Abstract P2-09-12: Independent validation of the HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancerPrat A, De Angelis C, Pascual T, Gutierrez C, Wang T, Paré L, Rexer B, Cortes J, Forero A, Llombart A, Wolff A, Krop I, Galván P, Pavlick A, Villagrasa P, Hilsenbeck S, Schiff R, Osborne C, Rimawi M. Abstract P2-09-12: Independent validation of the HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer Cancer Research 2018, 78: p2-09-12-p2-09-12. DOI: 10.1158/1538-7445.sabcs17-p2-09-12.
  • Abstract P5-20-01: Prolonged progression-free survival (PFS) in advanced HER2+ metastatic breast cancer with or without brain metastases: A pooled analysis of tucatinib phase 1b studiesHamilton E, Murthy R, Ferrario C, Conlin A, Krop I, Falkson C, Khan Q, Chamberlain M, Gray T, Borges V. Abstract P5-20-01: Prolonged progression-free survival (PFS) in advanced HER2+ metastatic breast cancer with or without brain metastases: A pooled analysis of tucatinib phase 1b studies Cancer Research 2018, 78: p5-20-01-p5-20-01. DOI: 10.1158/1538-7445.sabcs17-p5-20-01.
  • CMET-25. PROGRESSION-FREE SURVIVAL (PFS) AND SITE OF FIRST PROGRESSION IN HER2+ METASTATIC BREAST CANCER PATIENTS WITH OR WITHOUT BRAIN METASTASES: A POOLED ANALYSIS OF TUCATINIB PHASE I STUDIESHamilton E, Moulder S, Ferrario C, Conlin A, Krop I, Chamberlain M, Gray T, Borges V. CMET-25. PROGRESSION-FREE SURVIVAL (PFS) AND SITE OF FIRST PROGRESSION IN HER2+ METASTATIC BREAST CANCER PATIENTS WITH OR WITHOUT BRAIN METASTASES: A POOLED ANALYSIS OF TUCATINIB PHASE I STUDIES Neuro-Oncology 2017, 19: vi44-vi44. PMCID: PMC5692086, DOI: 10.1093/neuonc/nox168.173.
  • IN06 Optimal Sequence with and without Therapies for ABCKrop I. IN06 Optimal Sequence with and without Therapies for ABC The Breast 2017, 36: s20. DOI: 10.1016/s0960-9776(17)30626-4.
  • 324TiP PATINA: A randomized open label phase III trial to evaluate the efficacy and safety of palbociclib + anti HER2 therapy + endocrine therapy vs anti HER2 therapy + endocrine therapy after induction treatment for hormone receptor positive, HER2-positive metastatic breast cancerMetzger O, Mandrekar S, Ciruelos E, Loibl S, Valagussa P, Demichele A, Lim E, Tripathy D, Winer E, Huang C, Khoeler M, Carey L, Francis P, Miller K, Goel S, Goetz M, Prat A, Loi S, Krop I, Gianni L. 324TiP PATINA: A randomized open label phase III trial to evaluate the efficacy and safety of palbociclib + anti HER2 therapy + endocrine therapy vs anti HER2 therapy + endocrine therapy after induction treatment for hormone receptor positive, HER2-positive metastatic breast cancer Annals Of Oncology 2017, 28: v107-v108. DOI: 10.1093/annonc/mdx365.087.
  • 264P Progression-free survival (PFS) and site of first progression in HER2+ metastatic breast cancer (MBC) patients (pts) with (w) or without (w/o) brain metastases: A pooled analysis of tucatinib phase I studiesMoulder S, Hamilton E, Ferrario C, Conlin A, Krop I, Chamberlain M, Gray T, Borges V. 264P Progression-free survival (PFS) and site of first progression in HER2+ metastatic breast cancer (MBC) patients (pts) with (w) or without (w/o) brain metastases: A pooled analysis of tucatinib phase I studies Annals Of Oncology 2017, 28: v85. DOI: 10.1093/annonc/mdx365.027.
  • Abstract 4950: The emergence of ESR1 mutations is associated with aromatase inhibitor and fulvestrant therapyKuang Y, Siddiqui B, Hu J, Barry W, Lin N, Wagle N, Kirschmeier P, Jänne P, Paweletz C, Krop I, Winer E, Brown M, Jeselsohn R. Abstract 4950: The emergence of ESR1 mutations is associated with aromatase inhibitor and fulvestrant therapy Cancer Research 2017, 77: 4950-4950. DOI: 10.1158/1538-7445.am2017-4950.
  • Abstract CT055: A randomized, double-blinded, controlled study of tucatinib (ONT-380) vs. placebo in combination with capecitabine (C) and trastuzumab (Tz) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (MBC) (HER2CLIMB)Anders C, Murthy R, Hamilton E, Borges V, Cameron D, Carey L, Müller V, Curigliano G, Gelmon K, Hortobagyi G, Krop I, Loibl S, Pivot X, Pegram M, Slamon D, Hurvitz S, Tsai M, Winer E. Abstract CT055: A randomized, double-blinded, controlled study of tucatinib (ONT-380) vs. placebo in combination with capecitabine (C) and trastuzumab (Tz) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (MBC) (HER2CLIMB) Cancer Research 2017, 77: ct055-ct055. DOI: 10.1158/1538-7445.am2017-ct055.
  • TBCRC 022: Phase II trial of neratinib + capecitabine for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer brain metastases (BCBM).Freedman R, Gelman R, Melisko M, Anders C, Moy B, Blackwell K, Connolly R, Niravath P, Van Poznak C, Puhalla S, Farooq S, Cropp A, Cotter C, Liu M, Krop I, Nangia J, Tung N, Wolff A, Winer E, Lin N. TBCRC 022: Phase II trial of neratinib + capecitabine for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer brain metastases (BCBM). Journal Of Clinical Oncology 2017, 35: 1005-1005. DOI: 10.1200/jco.2017.35.15_suppl.1005.
  • A mouse-human phase I co-clinical trial of taselisib in combination with TDM1 in advanced HER2-positive breast cancer (MBC).Metzger Filho O, Goel S, Barry W, Hamilton E, Tolaney S, Yardley D, Rees R, Demeo M, Mills C, Hafner M, Winer E, Zhao J, Krop I. A mouse-human phase I co-clinical trial of taselisib in combination with TDM1 in advanced HER2-positive breast cancer (MBC). Journal Of Clinical Oncology 2017, 35: 1030-1030. DOI: 10.1200/jco.2017.35.15_suppl.1030.
  • A phase II study of eribulin mesylate in combination with trastuzumab and pertuzumab in patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC).Luis I, Guo H, Barry W, Krop I, Wagle N, Lowe A, Gore D, Andrews C, Osmani W, Isakoff S, Tung N, Winer E, Lin N, Freedman R. A phase II study of eribulin mesylate in combination with trastuzumab and pertuzumab in patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC). Journal Of Clinical Oncology 2017, 35: 1034-1034. DOI: 10.1200/jco.2017.35.15_suppl.1034.
  • Genome-wide copy number analysis of cell-free DNA from patients with chemotherapy-resistant metastatic triple-negative breast cancer.Stover D, Parsons H, Ha G, Freeman S, Barry W, Guo H, Gydush G, Reed S, Rhoades J, Rotem D, Hughes M, Krop I, Tolaney S, Wagle N, Getz G, Meyerson M, Love J, Winer E, Lin N, Adalsteinsson V. Genome-wide copy number analysis of cell-free DNA from patients with chemotherapy-resistant metastatic triple-negative breast cancer. Journal Of Clinical Oncology 2017, 35: 1092-1092. DOI: 10.1200/jco.2017.35.15_suppl.1092.
  • Seven-year (yr) follow-up of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC).Tolaney S, Barry W, Guo H, Dillon D, Dang C, Yardley D, Moy B, Marcom P, Albain K, Rugo H, Ellis M, Shapira I, Wolff A, Carey L, Overmoyer B, Partridge A, Hudis C, Krop I, Burstein H, Winer E. Seven-year (yr) follow-up of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC). Journal Of Clinical Oncology 2017, 35: 511-511. DOI: 10.1200/jco.2017.35.15_suppl.511.
  • Immune biomarkers and treatment (tx) outcome in hormone receptor-positive (HR+) breast cancer (BC) patients (pts) treated with preoperative chemotherapy (preop chemo) plus bevacizumab (bev).Waks A, Barry W, Gjini E, Dillon D, Rodig S, Brock J, Baltay M, Savoie J, Stover D, Winer E, Krop I, Tolaney S. Immune biomarkers and treatment (tx) outcome in hormone receptor-positive (HR+) breast cancer (BC) patients (pts) treated with preoperative chemotherapy (preop chemo) plus bevacizumab (bev). Journal Of Clinical Oncology 2017, 35: e12134-e12134. DOI: 10.1200/jco.2017.35.15_suppl.e12134.
  • A randomized, double-blinded, controlled study of tucatinib (ONT-380) vs. placebo in combination with capecitabine (C) and trastuzumab (Tz) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (mBC) (HER2CLIMB).Anders C, Murthy R, Hamilton E, Borges V, Cameron D, Carey L, Müller V, Curigliano G, Gelmon K, Hortobagyi G, Krop I, Loibl S, Pivot X, Pegram M, Slamon D, Hurvitz S, Tsai M, Winer E. A randomized, double-blinded, controlled study of tucatinib (ONT-380) vs. placebo in combination with capecitabine (C) and trastuzumab (Tz) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (mBC) (HER2CLIMB). Journal Of Clinical Oncology 2017, 35: tps1107-tps1107. DOI: 10.1200/jco.2017.35.15_suppl.tps1107.
  • TBCRC 036: Window of opportunity clinical trial reveals adaptive kinome reprogramming in single and combination HER2-targeting in breast cancer (BrCa).Angus S, Stuhlmiller T, Sciaky N, Chen X, Naim R, Tanioka M, Gallagher K, Forero A, Krop I, Thompson A, Murthy R, He X, Perou C, Earp S, Carey L, Johnson G. TBCRC 036: Window of opportunity clinical trial reveals adaptive kinome reprogramming in single and combination HER2-targeting in breast cancer (BrCa). Journal Of Clinical Oncology 2017, 35: 1027-1027. DOI: 10.1200/jco.2017.35.15_suppl.1027.
  • A phase I study of PF-06647263, a novel EFNA4-ADC, in patients with metastatic triple negative breast cancer.Garrido-Laguna I, Krop I, Burris H, Hamilton E, Braiteh F, Weise A, Abu-Khalaf M, Zopf C, Lakshminarayanan M, Holland J, Baffa R, Hong D, Hassan R. A phase I study of PF-06647263, a novel EFNA4-ADC, in patients with metastatic triple negative breast cancer. Journal Of Clinical Oncology 2017, 35: 2511-2511. DOI: 10.1200/jco.2017.35.15_suppl.2511.
  • Trastuzumab emtansine (T-DM1) and ribociclib, an oral inhibitor of cyclin dependent kinase 4 and 6 (CDK 4/6), for patients with metastatic HER2-positive breast cancer: Phase 1b clinical trial.Spring L, Goel S, Juric D, Isakoff S, Haddad S, Habin K, Krop I, Moy B, Tolaney S, Bardia A. Trastuzumab emtansine (T-DM1) and ribociclib, an oral inhibitor of cyclin dependent kinase 4 and 6 (CDK 4/6), for patients with metastatic HER2-positive breast cancer: Phase 1b clinical trial. Journal Of Clinical Oncology 2017, 35: tps1106-tps1106. DOI: 10.1200/jco.2017.35.15_suppl.tps1106.
  • SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA- mutant tumors.Baselga J, Cortés J, DeLaurentiis M, Dent S, Diéras V, Harbeck N, Hsu J, Jin H, Schimmoller F, Wilson T, Im Y, Jacot W, Krop I, Verma S. SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA- mutant tumors. Journal Of Clinical Oncology 2017, 35: tps1119-tps1119. DOI: 10.1200/jco.2017.35.15_suppl.tps1119.
  • Abstract OT1-02-09: A phase 2 randomized, double-blinded, controlled study of ONT-380 vs. placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (MBC) (HER2CLIMB)Hamilton E, Borges V, Murthy R, Anders C, Cameron D, Carey L, Müller V, Curigliano G, Gelmon K, Hortobagy G, Krop I, Loibl S, Pivort X, Pegram M, Slamon D, Hurvitz S, Tsai M, Winer E. Abstract OT1-02-09: A phase 2 randomized, double-blinded, controlled study of ONT-380 vs. placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (MBC) (HER2CLIMB) Cancer Research 2017, 77: ot1-02-09-ot1-02-09. DOI: 10.1158/1538-7445.sabcs16-ot1-02-09.
  • Abstract P1-12-04: Phase I dose-escalation trial of ONT-380 in combination with trastuzumab in patients (pts) with HER2+ breast cancer brain metastasesMetzger O, Barry W, Krop I, Guo H, Younger J, Lawler E, Walker L, Freedman R, Tolaney S, Winer E, Lin N. Abstract P1-12-04: Phase I dose-escalation trial of ONT-380 in combination with trastuzumab in patients (pts) with HER2+ breast cancer brain metastases Cancer Research 2017, 77: p1-12-04-p1-12-04. DOI: 10.1158/1538-7445.sabcs16-p1-12-04.
  • Abstract P2-08-01: Results from a randomized placebo-controlled phase 2 trial evaluating exemestane ± enzalutamide in patients with hormone receptor–positive breast cancerKrop I, Abramson V, Colleoni M, Holmes F, Estevez L, Hart L, Awada A, Zamagni C, Morris P, Schwartzberg L, Chan S, Wheatley D, Guculp A, Biganzoli L, Steinberg J, Gianni L, Trudeau M, Kelly C, Uppal H, Tudor I, Peterson A, Winer E, Yardley D. Abstract P2-08-01: Results from a randomized placebo-controlled phase 2 trial evaluating exemestane ± enzalutamide in patients with hormone receptor–positive breast cancer Cancer Research 2017, 77: p2-08-01-p2-08-01. DOI: 10.1158/1538-7445.sabcs16-p2-08-01.
  • Abstract S1-01: Whole exome and transcriptome sequencing of resistant ER+ metastatic breast cancerCohen O, Kim D, Oh C, Waks A, Oliver N, Helvie K, Marini L, Rotem A, Lloyd M, Stover D, Adalsteinsson V, Freeman S, Ha G, Cibulskis C, Anderka K, Tamayo P, Johannessen C, Krop I, Garraway L, Winer E, Lin N, Wagle N. Abstract S1-01: Whole exome and transcriptome sequencing of resistant ER+ metastatic breast cancer Cancer Research 2017, 77: s1-01-s1-01. DOI: 10.1158/1538-7445.sabcs16-s1-01.
  • Abstract S3-05: Integrated analysis of multidimensional genomic data on CALGB 40601 (Alliance), a randomized neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancerTanioka M, Fan C, Carey L, Hyslop T, Pitcher B, Parker J, Hoadley K, Henry N, Tolaney S, Dang C, Krop I, Harris L, Berry D, Mardis E, Perou C, Winer E, Hudis C. Abstract S3-05: Integrated analysis of multidimensional genomic data on CALGB 40601 (Alliance), a randomized neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer Cancer Research 2017, 77: s3-05-s3-05. DOI: 10.1158/1538-7445.sabcs16-s3-05.
  • Abstract P6-12-04: Phase 1 study of the antibody-drug conjugate (ADC) SGN-LIV1A in patients with heavily pretreated metastatic breast cancerForero-Torres A, Modi S, Specht J, Miller K, Weise A, Burris H, Liu M, Krop I, Pusztai L, Kostic A, Li M, Mita M. Abstract P6-12-04: Phase 1 study of the antibody-drug conjugate (ADC) SGN-LIV1A in patients with heavily pretreated metastatic breast cancer Cancer Research 2017, 77: p6-12-04-p6-12-04. DOI: 10.1158/1538-7445.sabcs16-p6-12-04.
  • Abstract OT2-01-01: SANDPIPER: Phase III study of the PI3-kinase inhibitor taselisib (GDC-0032) plus fulvestrant in patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer enriched for patients with PIK3CA- mutant tumorsBaselga J, Cortés J, De Laurentiis M, Dent S, Diéras V, Harbeck N, Hsu J, Jin H, Schimmoller F, Wilson T, Im Y, Jacot W, Krop I, Verma S. Abstract OT2-01-01: SANDPIPER: Phase III study of the PI3-kinase inhibitor taselisib (GDC-0032) plus fulvestrant in patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer enriched for patients with PIK3CA- mutant tumors Cancer Research 2017, 77: ot2-01-01-ot2-01-01. DOI: 10.1158/1538-7445.sabcs16-ot2-01-01.
  • Abstract P1-01-01: Circulating tumor cell number and CTC-endocrine therapy index predict clinical outcomes in ER positive metastatic breast cancer patients: Results of the COMETI Phase 2 trialPaoletti C, Regan M, Liu M, Marcom P, Hart L, Smith J, Tedesco K, Amir E, Krop I, DeMichele A, Goodwin P, Block M, Aung K, Cannell E, Darga E, Baratta P, Brown M, McCormack R, Hayes D. Abstract P1-01-01: Circulating tumor cell number and CTC-endocrine therapy index predict clinical outcomes in ER positive metastatic breast cancer patients: Results of the COMETI Phase 2 trial Cancer Research 2017, 77: p1-01-01-p1-01-01. DOI: 10.1158/1538-7445.sabcs16-p1-01-01.
  • Abstract P4-22-08: A single-arm phase 2 study to assess clinical activity, efficacy and safety of enzalutamide with trastuzumab in HER2+ AR+ metastatic or locally advanced breast cancerKrop I, Cortes J, Miller K, Huizing M, Provencher L, Gianni L, Chan S, Trudeau M, Steinberg J, Sugg J, Liosatos M, Paton V, Peterson A, Wardley A. Abstract P4-22-08: A single-arm phase 2 study to assess clinical activity, efficacy and safety of enzalutamide with trastuzumab in HER2+ AR+ metastatic or locally advanced breast cancer Cancer Research 2017, 77: p4-22-08-p4-22-08. DOI: 10.1158/1538-7445.sabcs16-p4-22-08.
  • Abstract P6-12-01: Phase II study of taselisib (GDC-0032) plus fulvestrant in HER2-negative, hormone receptor-positive advanced breast cancer: Analysis by PIK3CA and ESR1 mutation status from circulating tumor DNADickler M, Saura C, Oliveira M, Richards D, Krop I, Cervantes A, Stout T, Jin H, Savage H, Wilson T, Baselga J. Abstract P6-12-01: Phase II study of taselisib (GDC-0032) plus fulvestrant in HER2-negative, hormone receptor-positive advanced breast cancer: Analysis by PIK3CA and ESR1 mutation status from circulating tumor DNA Cancer Research 2017, 77: p6-12-01-p6-12-01. DOI: 10.1158/1538-7445.sabcs16-p6-12-01.
  • Abstract P4-21-40: In vitro and in vivo activity of HER2-targeted antibody-liposomal doxorubicin conjugate MM-302 in HER2-intermediate tumorsGeretti E, Espelin C, Adiwijaya B, Coma S, Koncki Z, Sumner P, Dumont N, Garcia G, Bloom T, Janovsky J, Reynolds J, Campbell K, Moyo V, Molnar I, LoRusso P, Krop I, Miller K, Ma C, Munster P, Wickham T. Abstract P4-21-40: In vitro and in vivo activity of HER2-targeted antibody-liposomal doxorubicin conjugate MM-302 in HER2-intermediate tumors Cancer Research 2017, 77: p4-21-40-p4-21-40. DOI: 10.1158/1538-7445.sabcs16-p4-21-40.
  • 313TiP SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with oestrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA-mutant tumoursBaselga J, Castan J, De Laurentiis M, Dieras V, Harbeck N, Hsu J, Jin H, Schimmoller F, Wilson T, Im Y, Jacot W, Krop I, Verma S. 313TiP SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with oestrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA-mutant tumours Annals Of Oncology 2016, 27: vi99. DOI: 10.1093/annonc/mdw365.92.
  • 315TiP HERMIONE: A phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician's choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and T-DM1Castan J, Verma S, Hurvitz S, Krop I, Tripathy D, Yardley D, Dionne M, Reynolds J, Wickham T, Molnar I, Miller K. 315TiP HERMIONE: A phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician's choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and T-DM1 Annals Of Oncology 2016, 27: vi99. DOI: 10.1093/annonc/mdw365.94.
  • 1560P Quantitative evaluation of HER2-mediated cellular uptake of the HER2-targeted antibody-liposomal doxorubicin conjugate MM-302 suggests potential for treating HER2-intermediate tumorsGeretti E, Espelin C, Adiwijaya B, Dumont N, Coma S, Koncki Z, Garcia G, Bloom T, Rimkunas V, Reynolds J, Campbell K, Moyo V, Molnar I, Lorusso P, Miller K, Ma C, Krop I, Munster P, Wickham T. 1560P Quantitative evaluation of HER2-mediated cellular uptake of the HER2-targeted antibody-liposomal doxorubicin conjugate MM-302 suggests potential for treating HER2-intermediate tumors Annals Of Oncology 2016, 27: vi539. DOI: 10.1093/annonc/mdw392.41.
  • Abstract LB-061: HER2-targeted PEGylated liposomal doxorubicin (MM-302) efficiently targets the HER2 intermediate cell population in vitro and in vivoGeretti E, Espelin C, Adiwijaya B, Dumont N, Coma S, Koncki Z, Pham M, Garcia G, Bloom T, Rimkunas V, Reynolds J, Campbell K, Moyo V, Molnar I, LoRusso P, Krop I, Miller K, Ma C, Munster P, Wickham T. Abstract LB-061: HER2-targeted PEGylated liposomal doxorubicin (MM-302) efficiently targets the HER2 intermediate cell population in vitro and in vivo Cancer Research 2016, 76: lb-061-lb-061. DOI: 10.1158/1538-7445.am2016-lb-061.
  • A cancer precision medicine platform for multiple simultaneous genomic assays from metastatic biopsies (bx) in ER+ metastatic breast cancer.Wagle N, Helvie K, Lloyd M, Marini L, Waks A, Cohen O, Oh C, Sougnez C, Oliver N, Quartey Q, Rotem A, Shah P, Lindeman N, Krop I, Garraway L, Winer E, Lin N. A cancer precision medicine platform for multiple simultaneous genomic assays from metastatic biopsies (bx) in ER+ metastatic breast cancer. Journal Of Clinical Oncology 2016, 34: 11513-11513. DOI: 10.1200/jco.2016.34.15_suppl.11513.
  • Mechanisms of resistance (MoR) to DNA damaging therapy (tx) in BRCA1/2-deficient (d) metastatic breast cancer (MBC).Waks A, Cohen O, Helvie K, Lloyd M, Marini L, Oh C, Oliver N, Lindeman N, Matulonis U, Krop I, Garraway L, Winer E, Lin N, Wagle N. Mechanisms of resistance (MoR) to DNA damaging therapy (tx) in BRCA1/2-deficient (d) metastatic breast cancer (MBC). Journal Of Clinical Oncology 2016, 34: 542-542. DOI: 10.1200/jco.2016.34.15_suppl.542.
  • Efficacy results of a phase 1b study of ONT-380, a CNS-penetrant TKI, in combination with T-DM1 in HER2+ metastatic breast cancer (MBC), including patients (pts) with brain metastases.Borges V, Ferrario C, Aucoin N, Falkson C, Khan Q, Krop I, Welch S, Bedard P, Conlin A, Chaves J, Walker L, Hamilton E. Efficacy results of a phase 1b study of ONT-380, a CNS-penetrant TKI, in combination with T-DM1 in HER2+ metastatic breast cancer (MBC), including patients (pts) with brain metastases. Journal Of Clinical Oncology 2016, 34: 513-513. DOI: 10.1200/jco.2016.34.15_suppl.513.
  • A phase II study of the PI3K inhibitor taselisib (GDC-0032) combined with fulvestrant (F) in patients (pts) with HER2-negative (HER2-), hormone receptor-positive (HR+) advanced breast cancer (BC).Dickler M, Saura C, Richards D, Krop I, Cervantes A, Bedard P, Patel M, Pusztai L, Oliveira M, Ware J, Jin H, Wilson T, Stout T, Wei M, Hsu J, Baselga J. A phase II study of the PI3K inhibitor taselisib (GDC-0032) combined with fulvestrant (F) in patients (pts) with HER2-negative (HER2-), hormone receptor-positive (HR+) advanced breast cancer (BC). Journal Of Clinical Oncology 2016, 34: 520-520. DOI: 10.1200/jco.2016.34.15_suppl.520.
  • SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA- mutant tumors.Baselga J, Cortes J, De Laurentiis M, Dieras V, Harbeck N, Hsu J, Ng V, Schimmoller F, Wilson T, Im Y, Jacot W, Krop I, Verma S. SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA- mutant tumors. Journal Of Clinical Oncology 2016, 34: tps617-tps617. DOI: 10.1200/jco.2016.34.15_suppl.tps617.
  • HERMIONE: A Phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician’s choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and ado-trastuzumab emtansine (T-DM1).Miller K, Cortes J, Hurvitz S, Krop I, Tripathy D, Verma S, Dionne M, Campbell K, Reynolds J, Wickham T, Molnar I, Yardley D. HERMIONE: A Phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician’s choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and ado-trastuzumab emtansine (T-DM1). Journal Of Clinical Oncology 2016, 34: tps631-tps631. DOI: 10.1200/jco.2016.34.15_suppl.tps631.
  • Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: American Society of Clinical Oncology Endorsement of Cancer Care Ontario Guideline Recommendations SummaryHenry N, Somerfield M, Krop I. Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: American Society of Clinical Oncology Endorsement of Cancer Care Ontario Guideline Recommendations Summary JCO Oncology Practice 2016, 12: 482-484. DOI: 10.1200/jop.2016.011205.
  • Clinical trial enrollment expansion to the community.Kostka J, Zerillo J, Kruse A, Sinclair N, Patrick M, McGovern L, Fuller F, O'Neil K, Hixon N, Weeks K, Johnson B, Krop I, Savoie J, Daftary F, Constantine M, Kaddis M, Rossi H, Tahir N, Norden A. Clinical trial enrollment expansion to the community. Journal Of Clinical Oncology 2016, 34: 112-112. DOI: 10.1200/jco.2016.34.7_suppl.112.
  • Abstract P4-14-20: A phase 1b study of ONT 380, an oral HER2-specific inhibitor, combined with ado trastuzumab emtansine (T DM1), in HER2+ metastatic breast cancer (MBC)Ferrario C, Hamilton E, Aucoin N, Falkson C, Khan Q, Krop I, Welch S, Bedard P, Conlin A, Chaves J, Vo A, Walker L, Borges V. Abstract P4-14-20: A phase 1b study of ONT 380, an oral HER2-specific inhibitor, combined with ado trastuzumab emtansine (T DM1), in HER2+ metastatic breast cancer (MBC) Cancer Research 2016, 76: p4-14-20-p4-14-20. DOI: 10.1158/1538-7445.sabcs15-p4-14-20.
  • Abstract OT1-03-14: SANDPIPER: Phase III study of the PI3-kinase inhibitor taselisib (GDC-0032) plus fulvestrant in patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer enriched for patients with PIK3CA -mutant tumorsBaselga J, Cortés J, De Laurentiis M, Diéras V, Harbeck N, Hsu J, Jin H, Schimmoller F, Wilson T, Im Y, Jacot W, Krop I, Verma S. Abstract OT1-03-14: SANDPIPER: Phase III study of the PI3-kinase inhibitor taselisib (GDC-0032) plus fulvestrant in patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer enriched for patients with PIK3CA -mutant tumors Cancer Research 2016, 76: ot1-03-14-ot1-03-14. DOI: 10.1158/1538-7445.sabcs15-ot1-03-14.
  • Abstract OT3-01-01: HERMIONE: A phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician's choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and ado-trastuzumab emtansine (T-DM1)Miller K, Cortes J, Hurvitz S, Krop I, Tripathy D, Verma S, Riahi K, Reynolds J, Wickham T, Molnar I, Yardley D. Abstract OT3-01-01: HERMIONE: A phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician's choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and ado-trastuzumab emtansine (T-DM1) Cancer Research 2016, 76: ot3-01-01-ot3-01-01. DOI: 10.1158/1538-7445.sabcs15-ot3-01-01.
  • Abstract P3-07-25: Improved clinical outcomes on enzalutamide observed in patients with PREDICT AR+ triple-negative breast cancer: prognosis or prediction?Miller K, Krop I, Schwartzberg L, Abramson V, Garcia-Estevez L, Eakle J, Nanda R, Yardley D, Ademuyiwa F, Chan S, Crown J, Danso M, Gelmon K, Ma L, Martinez-Janez N, Gradishar W, Steinberg J, Tudor I, Uppal H, Paton V, Parker J, Hudis C, Traina T. Abstract P3-07-25: Improved clinical outcomes on enzalutamide observed in patients with PREDICT AR+ triple-negative breast cancer: prognosis or prediction? Cancer Research 2016, 76: p3-07-25-p3-07-25. DOI: 10.1158/1538-7445.sabcs15-p3-07-25.
  • Abstract P4-14-01: Trastuzumab emtansine improves overall survival versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer: Final results from the phase 3 EMILIA studyDiéras V, Miles D, Verma S, Pegram M, Welslau M, Baselga J, Krop I, Blackwell K, Kang B, Xu J, Green M, Gianni L. Abstract P4-14-01: Trastuzumab emtansine improves overall survival versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer: Final results from the phase 3 EMILIA study Cancer Research 2016, 76: p4-14-01-p4-14-01. DOI: 10.1158/1538-7445.sabcs15-p4-14-01.
  • Abstract PD6-03: High prevalence and clonal heterogeneity of ESR1 mutations (mt) in circulating tumor DNA (ctDNA) from patients (pts) enrolled in FERGI, a randomized phase II study testing pictilisib (GDC-0941) in combination with fulvestrant (F) in pts that failed a prior aromatase inhibitor (AI)Spoerke J, Gendreau S, Johnston S, Schmid P, Krop I, Qui J, Derynck M, Chan I, Walter K, Amler L, Hampton G, Lackner M. Abstract PD6-03: High prevalence and clonal heterogeneity of ESR1 mutations (mt) in circulating tumor DNA (ctDNA) from patients (pts) enrolled in FERGI, a randomized phase II study testing pictilisib (GDC-0941) in combination with fulvestrant (F) in pts that failed a prior aromatase inhibitor (AI) Cancer Research 2016, 76: pd6-03-pd6-03. DOI: 10.1158/1538-7445.sabcs15-pd6-03.
  • Abstract S5-05: Trastuzumab emtansine improves overall survival versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer: Final overall survival results from the phase 3 TH3RESA studyWildiers H, Kim S, Gonzalez-Martin A, LoRusso P, Ferrero J, Yu R, Smitt M, Krop I. Abstract S5-05: Trastuzumab emtansine improves overall survival versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer: Final overall survival results from the phase 3 TH3RESA study Cancer Research 2016, 76: s5-05-s5-05. DOI: 10.1158/1538-7445.sabcs15-s5-05.
  • IN04 OPTIMAL MANAGEMENT OF HER-2+ ABCKrop I. IN04 OPTIMAL MANAGEMENT OF HER-2+ ABC The Breast 2015, 24: s22-s23. DOI: 10.1016/s0960-9776(15)30017-5.
  • Abstract 2399: Circulating tumor DNA (ctDNA) analysis of PIK3CA and AKT1 mutations in patients enrolled onto the Phase 1b study of the PI3K inhibitor taselisib (GDC-0032) in solid malignanciesWilson T, Savage H, Aimi J, Jin J, Parmar H, Hsu J, Krop I, Saura C, Cervantes A, Sachdev J, Patel M, Cejalvo J, Oliveira M, Winer E, Von Hoff D, Baselga J, Juric D. Abstract 2399: Circulating tumor DNA (ctDNA) analysis of PIK3CA and AKT1 mutations in patients enrolled onto the Phase 1b study of the PI3K inhibitor taselisib (GDC-0032) in solid malignancies 2015, 2399-2399. DOI: 10.1158/1538-7445.am2015-2399.
  • Abstract 2836: A discovery and validation set of breast cancer preoperative clinical trials show an increase in immune score upon brief-exposure to trastuzumab (T) and the HER2-enriched subtype predict response to combination chemotherapy and TVaradan V, Miskimen K, Parsai S, Krop I, Winer E, Bossuyt V, Abu-Khalaf M, Sikov W, Harris L. Abstract 2836: A discovery and validation set of breast cancer preoperative clinical trials show an increase in immune score upon brief-exposure to trastuzumab (T) and the HER2-enriched subtype predict response to combination chemotherapy and T 2015, 2836-2836. DOI: 10.1158/1538-7445.am2015-2836.
  • Abstract 2859: Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC)Emens L, Braiteh F, Cassier P, Delord J, Eder J, Fasso M, Xiao Y, Wang Y, Molinero L, Chen D, Krop I. Abstract 2859: Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC) 2015, 2859-2859. DOI: 10.1158/1538-7445.am2015-2859.
  • Abstract CT234: A phase I study of MM-302, a HER2-targeted PEGylated liposomal doxorubicin, in patients with HER2+ metastatic breast cancerLoRusso P, Krop I, Miller K, Ma C, Siegel B, Shields A, Molnar I, Wickham T, Reynolds J, Campbell K, Hendriks B, McClure T, Moyo V, Munster P. Abstract CT234: A phase I study of MM-302, a HER2-targeted PEGylated liposomal doxorubicin, in patients with HER2+ metastatic breast cancer 2015, ct234-ct234. DOI: 10.1158/1538-7445.am2015-ct234.
  • Whole exome sequencing (WES) in HER2+ metastatic breast cancer (MBC) patients (pts) with extraordinary responses to trastuzumab (T).Luis I, Oh C, Wang Z, Dipiro P, Macrae E, Painter C, Kryukov G, Krop I, Winer E, Lin N, Wagle N. Whole exome sequencing (WES) in HER2+ metastatic breast cancer (MBC) patients (pts) with extraordinary responses to trastuzumab (T). Journal Of Clinical Oncology 2015, 33: 611-611. DOI: 10.1200/jco.2015.33.15_suppl.611.
  • ONT-380 in the treatment of HER2+ breast cancer central nervous system (CNS) metastases (mets).Ferrario C, Welch S, Chaves J, Walker L, Krop I, Hamilton E, Borges V, Moulder S. ONT-380 in the treatment of HER2+ breast cancer central nervous system (CNS) metastases (mets). Journal Of Clinical Oncology 2015, 33: 612-612. DOI: 10.1200/jco.2015.33.15_suppl.612.
  • First-in-human dose escalation, safety, and PK study of a novel EFNA4-ADC in patients with advanced solid tumors.Hong D, Garrido-Laguna I, Krop I, Subbiah V, Werner T, Cotter C, Hamilton E, Velastegui K, Xuan D, Bugarini R, Gollerkeri A, Burris H. First-in-human dose escalation, safety, and PK study of a novel EFNA4-ADC in patients with advanced solid tumors. Journal Of Clinical Oncology 2015, 33: 2520-2520. DOI: 10.1200/jco.2015.33.15_suppl.2520.
  • HERMIONE: A Phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician’s choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and ado-trastuzumab emtansine (T-DM1).Miller K, Cortes J, Hurvitz S, Krop I, Tripathy D, Verma S, Riahi K, Reynolds J, Wickham T, Molnar I, Yardley D. HERMIONE: A Phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician’s choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and ado-trastuzumab emtansine (T-DM1). Journal Of Clinical Oncology 2015, 33: tps641-tps641. DOI: 10.1200/jco.2015.33.15_suppl.tps641.
  • Abstract P3-06-24: Brief exposure to trastuzumab prior to preoperative chemotherapy confirms predictors of response to treatmentVadodkar A, Varadan V, Miskimen K, Bossuyt V, Abu-khalaf M, Krop I, Winer E, Harris L. Abstract P3-06-24: Brief exposure to trastuzumab prior to preoperative chemotherapy confirms predictors of response to treatment 2015, p3-06-24-p3-06-24. DOI: 10.1158/1538-7445.sabcs14-p3-06-24.
  • Abstract P4-01-02: Prospective characterization of HER2-positive circulating tumor cells in patients with HER2-negative metastatic breast cancerKrop I, Macrae E, Galler S, Bischoff F, Fauni R, Sales E, Huynh L, Mitchell C, Clarin-Tamayo T, Anderson M, Abad L, Winer E. Abstract P4-01-02: Prospective characterization of HER2-positive circulating tumor cells in patients with HER2-negative metastatic breast cancer 2015, p4-01-02-p4-01-02. DOI: 10.1158/1538-7445.sabcs14-p4-01-02.
  • Abstract PD3-5: Whole exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients with or without prior trastuzumab (T): A correlative analysis of TBCRC003Wagle N, Lin N, Richardson A, Leshchiner I, Mayer I, Forero-Torres A, Hobday T, Dees E, Nanda R, Rimawi M, Guo H, Barry W, Bose R, Shen W, Wolff A, Gabriel S, Garraway L, Winer E, Krop I. Abstract PD3-5: Whole exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients with or without prior trastuzumab (T): A correlative analysis of TBCRC003 2015, pd3-5-pd3-5. DOI: 10.1158/1538-7445.sabcs14-pd3-5.
  • Abstract PD5-2: Ph1b study of the PI3K inhibitor taselisib (GDC-0032) in combination with letrozole in patients with hormone receptor-positive advanced breast cancerSaura C, Sachdev J, Patel M, Cervantes A, Juric D, Infante J, Richards D, Sanabria S, Lu X, Ware J, Wilson T, Parmar H, Hsu J, Oliveira M, Winer E, Von Hoff D, Baselga J, Krop I. Abstract PD5-2: Ph1b study of the PI3K inhibitor taselisib (GDC-0032) in combination with letrozole in patients with hormone receptor-positive advanced breast cancer 2015, pd5-2-pd5-2. DOI: 10.1158/1538-7445.sabcs14-pd5-2.
  • Abstract S3-06: Mutational analysis of CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancerHoadley K, Barry W, Pitcher B, Parker J, Wilkerson M, Irvin W, Henry N, Tolaney S, Dang C, Krop I, Berry D, Mardis E, Perou C, Winer E, Hudis C, Carey L. Abstract S3-06: Mutational analysis of CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer 2015, s3-06-s3-06. DOI: 10.1158/1538-7445.sabcs14-s3-06.
  • Abstract OT3-1-10: HERmione: A Phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with physician's choice of chemotherapy plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer, previously treated with peMiller K, Cortes J, Hurvitz S, Krop I, Tripathy D, Verma S, Riahi K, Yardley D. Abstract OT3-1-10: HERmione: A Phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with physician's choice of chemotherapy plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer, previously treated with pe 2015, ot3-1-10-ot3-1-10. DOI: 10.1158/1538-7445.sabcs14-ot3-1-10.
  • Abstract P3-11-03: A randomized, phase 2 trial of preoperative MM-121 with paclitaxel in triple negative (TN) and hormone receptor (HR) positive, HER2-negative breast cancerHolmes F, McIntyre K, Krop I, Osborne C, Smith II J, Modiano M, Gupta M, Downey L, Nanda R, Saleh M, Young J, Horgan K, Kubasek W, MacBeath G, Danso M, O'Shaughnessy J. Abstract P3-11-03: A randomized, phase 2 trial of preoperative MM-121 with paclitaxel in triple negative (TN) and hormone receptor (HR) positive, HER2-negative breast cancer 2015, p3-11-03-p3-11-03. DOI: 10.1158/1538-7445.sabcs14-p3-11-03.
  • Abstract P4-15-04: Effect of pre-treatment with cyclophosphamide on MM-302 (HER2-targeted liposomal doxorubicin) deposition in HER2-positive metastatic breast cancer patients assessed by 64 Cu-MM-302 PET/CTMiller K, LoRusso P, Munster P, Krop I, Ma C, Lee H, Reynolds J, Campbell K, Moyo V, Hendriks B, Wickham T, Siegel B, Shields A. Abstract P4-15-04: Effect of pre-treatment with cyclophosphamide on MM-302 (HER2-targeted liposomal doxorubicin) deposition in HER2-positive metastatic breast cancer patients assessed by 64 Cu-MM-302 PET/CT 2015, p4-15-04-p4-15-04. DOI: 10.1158/1538-7445.sabcs14-p4-15-04.
  • Abstract P4-15-08: A phase 1b study of ONT-380, an oral HER2-specific inhibitor, combined with ado-trastuzumab emtansine (T-DM1), in HER2+ metastatic breast cancer (MBC)Borges V, Hamilton E, Yardley D, Chaves J, Aucoin N, Ferrario C, Walker L, Krop I. Abstract P4-15-08: A phase 1b study of ONT-380, an oral HER2-specific inhibitor, combined with ado-trastuzumab emtansine (T-DM1), in HER2+ metastatic breast cancer (MBC) 2015, p4-15-08-p4-15-08. DOI: 10.1158/1538-7445.sabcs14-p4-15-08.
  • Abstract PD1-6: Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancerEmens L, Braiteh F, Cassier P, DeLord J, Eder J, Shen X, Xiao Y, Wang Y, Hegde P, Chen D, Krop I. Abstract PD1-6: Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer 2015, pd1-6-pd1-6. DOI: 10.1158/1538-7445.sabcs14-pd1-6.
  • Abstract S6-02: TBCRC023: A randomized multicenter phase II neoadjuvant trial of lapatinib plus trastuzumab, with endcorine therapy and without chemotherapy, for 12 vs. 24 weeks in patients with HER2 overexpressing breast cancerRimawi M, Niravath P, Wang T, Rexer B, Forero A, Wolff A, Nanda R, Storniolo A, Krop I, Goetz M, Nangia J, Jiralerspong S, Pavlick A, Gutierrez C, Schiff R, Hilsenbeck S, Osborne C. Abstract S6-02: TBCRC023: A randomized multicenter phase II neoadjuvant trial of lapatinib plus trastuzumab, with endcorine therapy and without chemotherapy, for 12 vs. 24 weeks in patients with HER2 overexpressing breast cancer 2015, s6-02-s6-02. DOI: 10.1158/1538-7445.sabcs14-s6-02.
  • Current Perspectives on HER2-Positive BCParry N, Moasser M, Loibl S, Krop I. Current Perspectives on HER2-Positive BC MD Conference Express 2014, 14: 17-18. DOI: 10.1177/1559897715572117.
  • NI-23BRAIN BREAST METASTASES RESPOND TO ANTI-ANGIOGENIC THERAPY BY MODES OF VASCULAR NORMALIZATIONEmblem K, Pinho M, Chandra V, Gerstner E, Stufflebeam S, Sorenson G, Harris G, Freedman R, Sohl J, Younger J, Krop I, Winer E, Lin N. NI-23BRAIN BREAST METASTASES RESPOND TO ANTI-ANGIOGENIC THERAPY BY MODES OF VASCULAR NORMALIZATION Neuro-Oncology 2014, 16: v143-v143. PMCID: PMC4218348, DOI: 10.1093/neuonc/nou264.22.
  • Abstract 915: Expanded biomarker results from a phase I dose escalation study of GDC-0032, a beta isoform-sparing PI3K inhibitorWilson T, Savage H, O'Brien C, Sanabria S, Lin R, Wagle M, Yan Y, Lackner M, Parmar H, Hsu J, Juric D, Krop I, Ramanathan R, Hoff D, Baselga J. Abstract 915: Expanded biomarker results from a phase I dose escalation study of GDC-0032, a beta isoform-sparing PI3K inhibitor 2014, 915-915. DOI: 10.1158/1538-7445.am2014-915.
  • Patient-reported outcomes (PROs) from TH3RESA, a phase 3 study of trastuzumab emtansine (T-DM1) versus treatment of physician’s choice (TPC) in patients with pretreated HER2-positive advanced breast cancer.Bartley K, Wildiers H, Kim S, Krop I, Kang J, Yu R, Leung A, Trudeau C, Gonzalez-Martin A. Patient-reported outcomes (PROs) from TH3RESA, a phase 3 study of trastuzumab emtansine (T-DM1) versus treatment of physician’s choice (TPC) in patients with pretreated HER2-positive advanced breast cancer. Journal Of Clinical Oncology 2014, 32: 153-153. DOI: 10.1200/jco.2014.32.26_suppl.153.
  • A phase II study of tivantinib (ARQ-197) for metastatic triple-negative breast cancer.Tolaney S, Guo H, Barry W, Larrabee K, Brock J, Wagle N, Van Allen E, Paweletz C, Ivanova E, Janne P, Overmoyer B, Wright J, Shapiro G, Winer E, Krop I. A phase II study of tivantinib (ARQ-197) for metastatic triple-negative breast cancer. Journal Of Clinical Oncology 2014, 32: 1106-1106. DOI: 10.1200/jco.2014.32.15_suppl.1106.
  • Gene expression signatures in pre- and post-therapy (Rx) specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (BrCa).Carey L, Barry W, Pitcher B, Hoadley K, Cheang M, Anders C, Henry N, Tolaney S, Dang C, Krop I, Harris L, Berry D, Perou C, Winer E, Hudis C. Gene expression signatures in pre- and post-therapy (Rx) specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (BrCa). Journal Of Clinical Oncology 2014, 32: 506-506. DOI: 10.1200/jco.2014.32.15_suppl.506.
  • TBCRC 022: Phase II trial of neratinib for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer and brain metastases (BCBM).Freedman R, Gelman R, Wefel J, Krop I, Melisko M, Lowe A, Agar N, Blackwell K, Connolly R, Niravath P, Van Poznak C, Puhalla S, Ryabin N, Lawler E, Ibrahim N, Liu M, Wolff A, Winer E, Lin N. TBCRC 022: Phase II trial of neratinib for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer and brain metastases (BCBM). Journal Of Clinical Oncology 2014, 32: 528-528. DOI: 10.1200/jco.2014.32.15_suppl.528.
  • Whole-exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients (pts) treated with prior trastuzumab (T): A correlative analysis of TBCRC003.Wagle N, Lin N, Richardson A, Leshchiner I, Mayer I, Forero-Torres A, Hobday T, Dees E, Nanda R, Rimawi M, Guo H, Barry W, Wolff A, Gabriel S, Garraway L, Winer E, Krop I. Whole-exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients (pts) treated with prior trastuzumab (T): A correlative analysis of TBCRC003. Journal Of Clinical Oncology 2014, 32: 536-536. DOI: 10.1200/jco.2014.32.15_suppl.536.
  • Phase I dose-escalation trial of ONT-380 in combination with trastuzumab in participants with brain metastases from HER2+ breast cancer.Metzger-Filho O, Barry W, Krop I, Younger W, Lawler E, Winer E, Lin N. Phase I dose-escalation trial of ONT-380 in combination with trastuzumab in participants with brain metastases from HER2+ breast cancer. Journal Of Clinical Oncology 2014, 32: tps660-tps660. DOI: 10.1200/jco.2014.32.15_suppl.tps660.
  • A phase II study of eribulin mesylate in combination with trastuzumab and pertuzumab in patients (pts) with metastatic, human epidermal growth factor receptor 2-positive breast cancer.Freedman R, Luis I, Barry W, Krop I, Wagle N, Lowe A, Galler S, Sohl J, Isakoff S, Tung N, Winer E, Lin N. A phase II study of eribulin mesylate in combination with trastuzumab and pertuzumab in patients (pts) with metastatic, human epidermal growth factor receptor 2-positive breast cancer. Journal Of Clinical Oncology 2014, 32: tps668-tps668. DOI: 10.1200/jco.2014.32.15_suppl.tps668.
  • Relationship between tumor biomarkers (BM) and efficacy in TH3RESA, a phase 3 study of trastuzumab emtansine (T-DM1) versus treatment of physician’s choice (TPC) in HER2-positive advanced breast cancer (BC) previously treated with trastuzumab and lapatinib.Kim S, Wildiers H, Krop I, Leung A, Trudeau C, Yu R, de Haas S, Gonzalez-Martin A. Relationship between tumor biomarkers (BM) and efficacy in TH3RESA, a phase 3 study of trastuzumab emtansine (T-DM1) versus treatment of physician’s choice (TPC) in HER2-positive advanced breast cancer (BC) previously treated with trastuzumab and lapatinib. Journal Of Clinical Oncology 2014, 32: 605-605. DOI: 10.1200/jco.2014.32.15_suppl.605.
  • A phase 1b study of ONT-380, an oral HER2-specific inhibitor, combined with ado-trastuzumab emtansine (T-DM1), in HER2+ metastatic breast cancer (MBC).Borges V, Hamilton E, Yardley D, Moulder S, Hortobagyi G, Walker L, Krop I. A phase 1b study of ONT-380, an oral HER2-specific inhibitor, combined with ado-trastuzumab emtansine (T-DM1), in HER2+ metastatic breast cancer (MBC). Journal Of Clinical Oncology 2014, 32: tps662-tps662. DOI: 10.1200/jco.2014.32.15_suppl.tps662.
  • Abstract OT3-2-05: Randomized phase II study of fulvestrant with or without ganetespib in patients (pts) with hormone receptor (HR)-positive metastatic breast cancerLin N, Whitesell L, Gelman R, Mayer E, Krop I, Santagata S, Lowe A, Proia D, Farooq S, Brown M, Iannone M, Lindquist S, Winer E. Abstract OT3-2-05: Randomized phase II study of fulvestrant with or without ganetespib in patients (pts) with hormone receptor (HR)-positive metastatic breast cancer Cancer Research 2013, 73: ot3-2-05-ot3-2-05. DOI: 10.1158/0008-5472.sabcs13-ot3-2-05.
  • Abstract P3-08-05: Chemotherapy-related amenorrhea on adjuvant paclitaxel-trastuzumab (APT trial)Ruddy K, Tolaney S, Guo H, Dang C, Yardley D, Moy B, Marcom P, Albain K, Rugo H, Ellis M, Shapira I, Wolff A, Carey L, Overmoyer B, Hudis C, Krop I, Burstein H, Winer E, Partridge A. Abstract P3-08-05: Chemotherapy-related amenorrhea on adjuvant paclitaxel-trastuzumab (APT trial) Cancer Research 2013, 73: p3-08-05-p3-08-05. DOI: 10.1158/0008-5472.sabcs13-p3-08-05.
  • Abstract S1-04: A phase II study of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC)Tolaney S, Barry W, Dang C, Yardley D, Moy B, Marcom P, Albain K, Rugo H, Ellis M, Shapira I, Wolff A, Carey L, Overmoyer B, Partridge A, Guo H, Hudis C, Krop I, Burstein H, Winer E. Abstract S1-04: A phase II study of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC) Cancer Research 2013, 73: s1-04-s1-04. DOI: 10.1158/0008-5472.sabcs13-s1-04.
  • Abstract P2-15-03: Cardiac safety of trastuzumab emtansine (T-DM1) following anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive (HER2+) early-stage breast cancer (EBC): Final data from TDM4874gKrop I, Suter T, Dirix L, Romieu G, Zamagni C, Citron M, Campone M, Dang C, Xu N, Smitt M, Gianni L. Abstract P2-15-03: Cardiac safety of trastuzumab emtansine (T-DM1) following anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive (HER2+) early-stage breast cancer (EBC): Final data from TDM4874g Cancer Research 2013, 73: p2-15-03-p2-15-03. DOI: 10.1158/0008-5472.sabcs13-p2-15-03.
  • Abstract P4-12-09: Results from a phase 2a study of trastuzumab emtansine, paclitaxel, and pertuzumab in patients with HER2-positive metastatic breast cancerElias A, Modi S, Krop I, Pegram M, Ipe D, Guardino E, Althaus B, LoRusso P. Abstract P4-12-09: Results from a phase 2a study of trastuzumab emtansine, paclitaxel, and pertuzumab in patients with HER2-positive metastatic breast cancer Cancer Research 2013, 73: p4-12-09-p4-12-09. DOI: 10.1158/0008-5472.sabcs13-p4-12-09.
  • Abstract P4-12-27: Efficacy and safety of trastuzumab emtansine (T-DM1) vs lapatinib plus capecitabine (XL) in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) and central nervous system (CNS) metastases: Results from a retrospective exploratory analysis of EMILIAKrop I, Lin N, Blackwell K, Guardino E, Huober J, Lu M, Miles D, Samant M, Welslau M, Diéras V. Abstract P4-12-27: Efficacy and safety of trastuzumab emtansine (T-DM1) vs lapatinib plus capecitabine (XL) in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) and central nervous system (CNS) metastases: Results from a retrospective exploratory analysis of EMILIA Cancer Research 2013, 73: p4-12-27-p4-12-27. DOI: 10.1158/0008-5472.sabcs13-p4-12-27.
  • Abstract P4-12-29: Assessment of safety and activity in an expanded phase 1 study of MM-302, a HER2-targeted liposomal doxorubicin, in patients with advanced HER2-positive (HER2+) breast cancerMunster P, Krop I, Miller K, Dhindsa N, Niyijiza C, Nielsen U, Odueyungbo A, Rajarethinam A, Marande M, Campbell K, Geretti E, Reynolds J, Hendriks B, Wickham T, Moyo V, LoRusso P. Abstract P4-12-29: Assessment of safety and activity in an expanded phase 1 study of MM-302, a HER2-targeted liposomal doxorubicin, in patients with advanced HER2-positive (HER2+) breast cancer Cancer Research 2013, 73: p4-12-29-p4-12-29. DOI: 10.1158/0008-5472.sabcs13-p4-12-29.
  • Abstract PD1-3: Ph1b study of the PI3K inhibitor GDC-0032 in combination with fulvestrant in patients with hormone receptor-positive advanced breast cancerJuric D, Saura C, Cervantes A, Kurkjian C, Patel M, Sachdev J, Mayer I, Krop I, Oliveira M, Sanabria S, Cheeti S, Lin R, Graham R, Wilson T, Parmar H, Hsu J, Von Hoff D, Baselga J. Abstract PD1-3: Ph1b study of the PI3K inhibitor GDC-0032 in combination with fulvestrant in patients with hormone receptor-positive advanced breast cancer Cancer Research 2013, 73: pd1-3-pd1-3. DOI: 10.1158/0008-5472.sabcs13-pd1-3.
  • Trastuzumab emtansine (T-DM1) in previously treated HER2-positive metastatic breast cancer (MBC): Results from an expanded access study.Yardley D, Krop I, LoRusso P, Robert N, Mayer M, Abidoye O, Lai C, Yoo B, Perez E. Trastuzumab emtansine (T-DM1) in previously treated HER2-positive metastatic breast cancer (MBC): Results from an expanded access study. Journal Of Clinical Oncology 2013, 31: 166-166. DOI: 10.1200/jco.2013.31.26_suppl.166.
  • Differential changes in tissue biomarkers after bevacizumab (BEV) alone in a neoadjuvant study of BEV and chemotherapy in ER+ breast cancer (BC) versus triple-negative breast cancer (TNBC) patients (pts).Boucher Y, Martin J, Tolaney S, Ancukiewicz M, Seano G, Goel S, Yeh E, Meyer J, Isakoff S, Duda D, Winer E, Krop I, Jain R. Differential changes in tissue biomarkers after bevacizumab (BEV) alone in a neoadjuvant study of BEV and chemotherapy in ER+ breast cancer (BC) versus triple-negative breast cancer (TNBC) patients (pts). Journal Of Clinical Oncology 2013, 31: 1065-1065. DOI: 10.1200/jco.2013.31.15_suppl.1065.
  • Neoadjuvant bevacizumab: Surgical complications of mastectomy with and without reconstruction.Kansal K, Dominici L, Tolaney S, Isakoff S, Krop I, Smith B, Jiang W, Potler H, Brock J, Winer E, Golshan M. Neoadjuvant bevacizumab: Surgical complications of mastectomy with and without reconstruction. Journal Of Clinical Oncology 2013, 31: 1100-1100. DOI: 10.1200/jco.2013.31.15_suppl.1100.
  • Clinical and translational results of CALGB 40601: A neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer.Carey L, Berry D, Ollila D, Harris L, Krop I, Weckstein D, Henry N, Anders C, Cirrincione C, Winer E, Perou C, Hudis C. Clinical and translational results of CALGB 40601: A neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer. Journal Of Clinical Oncology 2013, 31: 500-500. DOI: 10.1200/jco.2013.31.15_suppl.500.
  • Phase II trial of carboplatin (C) and bevacizumab (BEV) in patients (pts) with breast cancer brain metastases (BCBM).Lin N, Gelman R, Younger W, Sohl J, Freedman R, Sorensen A, Bullitt E, Harris G, Morganstern D, Schneider B, Krop I, Winer E. Phase II trial of carboplatin (C) and bevacizumab (BEV) in patients (pts) with breast cancer brain metastases (BCBM). Journal Of Clinical Oncology 2013, 31: 513-513. DOI: 10.1200/jco.2013.31.15_suppl.513.
  • Prospective clinical experience with research biopsies in breast cancer patients.Zeghibe C, Luis I, Frank E, Sohl J, Washington K, Silverman S, Fonte J, Mayer E, Overmoyer B, Richardson A, Krop I, Winer E, Lin N. Prospective clinical experience with research biopsies in breast cancer patients. Journal Of Clinical Oncology 2013, 31: e17574-e17574. DOI: 10.1200/jco.2013.31.15_suppl.e17574.
  • Phase II study of ruxolitinib in patients with pStat3+ breast cancer.Lin N, Gelman R, Brock J, Bardia A, Mayer E, Overmoyer B, Wang V, Iannone M, Krop I, Polyak K, Winer E. Phase II study of ruxolitinib in patients with pStat3+ breast cancer. Journal Of Clinical Oncology 2013, 31: tps1134-tps1134. DOI: 10.1200/jco.2013.31.15_suppl.tps1134.
  • Beyond Trastuzumab and Lapatinib: New Options for HER2-Positive Breast CancerZardavas D, Cameron D, Krop I, Piccart M. Beyond Trastuzumab and Lapatinib: New Options for HER2-Positive Breast Cancer American Society Of Clinical Oncology Educational Book 2013, e2-e11. DOI: 10.14694/edbook_am.2013.33.e2.
  • Abstract LB-76: Tissue biomarkers and interstitial fluid pressure in a phase II study of preoperative (preop) bevacizumab (bev) followed by dose-dense doxorubicin (A)/cyclophosphamide (C)/paclitaxel (T) in combination with bev in HER2-negative operable breast cancer (BC)Boucher Y, Martin J, Tolaney S, Seano G, Goel S, Ancukiewicz M, Isakoff S, Winer E, Krop I, Jain R. Abstract LB-76: Tissue biomarkers and interstitial fluid pressure in a phase II study of preoperative (preop) bevacizumab (bev) followed by dose-dense doxorubicin (A)/cyclophosphamide (C)/paclitaxel (T) in combination with bev in HER2-negative operable breast cancer (BC) Cancer Research 2013, 73: lb-76-lb-76. DOI: 10.1158/1538-7445.am2013-lb-76.
  • Abstract LB-81: A study of circulating biomarkers of angiogenesis and inflammation in ER+ breast cancer (BC) versus triple-negative breast cancer (TNBC) patients enrolled in a phase II study of preoperative treatment with 1 cycle of Bevacizumab followed by standard chemoDuda D, Tolaney S, Ancukiewicz M, Winer E, Krop I, Jain R. Abstract LB-81: A study of circulating biomarkers of angiogenesis and inflammation in ER+ breast cancer (BC) versus triple-negative breast cancer (TNBC) patients enrolled in a phase II study of preoperative treatment with 1 cycle of Bevacizumab followed by standard chemo Cancer Research 2013, 73: lb-81-lb-81. DOI: 10.1158/1538-7445.am2013-lb-81.
  • Abstract LB-64: GDC-0032, a beta isoform-sparing PI3K inhibitor: Results of a first-in-human phase Ia dose escalation study.Juric D, Krop I, Ramanathan R, Xiao J, Sanabria S, Wilson T, Choi Y, Parmar H, Hsu J, Baselga J, Von Hoff D. Abstract LB-64: GDC-0032, a beta isoform-sparing PI3K inhibitor: Results of a first-in-human phase Ia dose escalation study. Cancer Research 2013, 73: lb-64-lb-64. DOI: 10.1158/1538-7445.am2013-lb-64.
  • Abstract OT1-1-11: TBCRC 022: Phase II Trial of Neratinib for Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast cancer and Brain MetastasesFreedman R, Gelman R, Wefel J, Krop I, Melisko M, Ly A, Agar N, Connolly R, Blackwell K, Nabell L, Ingle J, Van Poznak C, Puhalla S, Niravath P, Ryabin N, Wolff A, Winer E, Lin N. Abstract OT1-1-11: TBCRC 022: Phase II Trial of Neratinib for Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast cancer and Brain Metastases Cancer Research 2012, 72: ot1-1-11-ot1-1-11. DOI: 10.1158/0008-5472.sabcs12-ot1-1-11.
  • Abstract P3-05-03: Characterization of PIK3CA mutations in lobular breast cancerDesmedt C, Metzger O, Fumagalli D, Brown D, Singhal S, Vincent D, Adnet P, Smeets D, Bertucci F, Galant C, Salgado R, Veys I, Saini K, Pruneri G, Krop I, Winer E, Michiels S, Piccart M, Lambrechts D, Larsimont D, Viale G, Sotiriou C. Abstract P3-05-03: Characterization of PIK3CA mutations in lobular breast cancer Cancer Research 2012, 72: p3-05-03-p3-05-03. DOI: 10.1158/0008-5472.sabcs12-p3-05-03.
  • Abstract P5-18-03: Clinicopathological features among patients with HER2-positive breast cancer with prolonged response to trastuzumab based therapyVaz-Luis I, Seah D, Olson E, Metzger O, Wagle N, Sohl J, Litsas G, Burstein H, Krop I, Winer E, Lin N. Abstract P5-18-03: Clinicopathological features among patients with HER2-positive breast cancer with prolonged response to trastuzumab based therapy Cancer Research 2012, 72: p5-18-03-p5-18-03. DOI: 10.1158/0008-5472.sabcs12-p5-18-03.
  • Abstract P5-18-06: Trastuzumab emtansine in HER2-positive metastatic breast cancer: pooled safety analysis from seven studiesDiéras V, Harbeck N, Budd G, Greenson J, Guardino E, Samant M, Chernyukhin N, Smitt M, Krop I. Abstract P5-18-06: Trastuzumab emtansine in HER2-positive metastatic breast cancer: pooled safety analysis from seven studies Cancer Research 2012, 72: p5-18-06-p5-18-06. DOI: 10.1158/0008-5472.sabcs12-p5-18-06.
  • Trastuzumab Emtansine (T-DM1) for the Treatment of HER2-Positive Cancer with a Focus on Breast CancerRugo H, Krop I, Chu Y. Trastuzumab Emtansine (T-DM1) for the Treatment of HER2-Positive Cancer with a Focus on Breast Cancer 2012, 179-210. DOI: 10.1007/978-1-4614-5456-4_11.
  • Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane.Pegram M, Blackwell K, Miles D, Bianchi G, Krop I, Welslau M, Baselga J, Oh D, Dieras V, Guardino E, Olsen S, Fang L, Lu M, Verma S. Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane. Journal Of Clinical Oncology 2012, 30: 98-98. DOI: 10.1200/jco.2012.30.27_suppl.98.
  • LBA12 Results from Emilia, A Phase 3 Study of Trastuzumab Emtansine (T-DM1) vs Capecitabine (X) and Lapatinib (L) in Her2-Positive Locally Advanced or Metastatic Breast Cancer (MBC)Verma S, Miles D, Gianni L, Krop I, Welslau M, Baselga J, Pegram M, Oh D, Diéras V, Guardino E, Fang L, Lu M, Olsen S, Blackwell K. LBA12 Results from Emilia, A Phase 3 Study of Trastuzumab Emtansine (T-DM1) vs Capecitabine (X) and Lapatinib (L) in Her2-Positive Locally Advanced or Metastatic Breast Cancer (MBC) Annals Of Oncology 2012, 23: ixe5-ixe6. DOI: 10.1016/s0923-7534(20)34362-3.
  • Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane.Blackwell K, Miles D, Gianni L, Krop I, Welslau M, Baselga J, Pegram M, Oh D, Dieras V, Olsen S, Fang L, Lu M, Guardino E, Verma S. Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane. Journal Of Clinical Oncology 2012, 30: lba1-lba1. DOI: 10.1200/jco.2012.30.18_suppl.lba1.
  • A phase II study of preoperative (preop) bevacizumab (bev) followed by dose-dense (dd) doxorubicin (A)/cyclophosphamide (C)/paclitaxel (T) in combination with bev in HER2-negative operable breast cancer (BC).Tolaney S, Duda D, Boucher Y, Goel S, Martin J, Ancukiewicz M, Potler H, Incio J, Ligibel J, Isakoff S, Fukumura D, Winer E, Krop I, Jain R. A phase II study of preoperative (preop) bevacizumab (bev) followed by dose-dense (dd) doxorubicin (A)/cyclophosphamide (C)/paclitaxel (T) in combination with bev in HER2-negative operable breast cancer (BC). Journal Of Clinical Oncology 2012, 30: 1026-1026. DOI: 10.1200/jco.2012.30.15_suppl.1026.
  • Evaluation of gene expression by RNA-seq after single dose of trastuzumab (T) reveals predictors of pathologic complete response (pCR) in HER2-positive early breast cancer.Galanina N, Sprecher E, Bossuyt V, Sarkar S, Krop I, Winer E, Tuck D, Bruce C, Harris L. Evaluation of gene expression by RNA-seq after single dose of trastuzumab (T) reveals predictors of pathologic complete response (pCR) in HER2-positive early breast cancer. Journal Of Clinical Oncology 2012, 30: 10558-10558. DOI: 10.1200/jco.2012.30.15_suppl.10558.
  • A phase I/IB dose-escalation study of BEZ235 in combination with trastuzumab in patients with PI3-kinase or PTEN altered HER2+ metastatic breast cancer.Krop I, Saura C, Rodon Ahnert J, Becerra C, Britten C, Isakoff S, Demanse D, Hackl W, Quadt C, Silva A, Burris H, Abu-Khalaf M, Baselga J. A phase I/IB dose-escalation study of BEZ235 in combination with trastuzumab in patients with PI3-kinase or PTEN altered HER2+ metastatic breast cancer. Journal Of Clinical Oncology 2012, 30: 508-508. DOI: 10.1200/jco.2012.30.15_suppl.508.
  • Results from a phase Ib study of trastuzumab emtansine (T-DM1), paclitaxel (T), and pertuzumab (P) in patients with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab.Modi S, Elias A, LoRusso P, Samant M, Guardino E, Althaus B, Krop I. Results from a phase Ib study of trastuzumab emtansine (T-DM1), paclitaxel (T), and pertuzumab (P) in patients with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab. Journal Of Clinical Oncology 2012, 30: 528-528. DOI: 10.1200/jco.2012.30.15_suppl.528.
  • Cardiac safety in a phase II study of trastuzumab emtansine (T-DM1) following anthracycline-based chemotherapy as adjuvant or neoadjuvant therapy for early-stage HER2-positive breast cancer.Dang C, Gianni L, Romieu G, Dirix L, Campone M, Citron M, Zamagni C, Krop I, Xu N, Smitt M, Suter T. Cardiac safety in a phase II study of trastuzumab emtansine (T-DM1) following anthracycline-based chemotherapy as adjuvant or neoadjuvant therapy for early-stage HER2-positive breast cancer. Journal Of Clinical Oncology 2012, 30: 532-532. DOI: 10.1200/jco.2012.30.15_suppl.532.
  • Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane.Blackwell K, Miles D, Gianni L, Krop I, Welslau M, Baselga J, Pegram M, Oh D, Dieras V, Olsen S, Fang L, Lu M, Guardino E, Verma S. Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane. Journal Of Clinical Oncology 2012, 30: lba1-lba1. DOI: 10.1200/jco.2012.30.15_suppl.lba1.
  • A phase I study of MM-302, a HER2-targeted liposomal doxorubicin, in patients with advanced, HER2-positive (HER2+) breast cancer.Munster P, Miller K, Krop I, Dhindsa N, Reynolds J, Geretti E, Niyikiza C, Nielsen U, Hendriks B, Wickham T, Moyo V, LoRusso P. A phase I study of MM-302, a HER2-targeted liposomal doxorubicin, in patients with advanced, HER2-positive (HER2+) breast cancer. Journal Of Clinical Oncology 2012, 30: tps663-tps663. DOI: 10.1200/jco.2012.30.15_suppl.tps663.
  • Abstract LB-231: Phase Ib dose escalation and biomarker study of MK2206 in combination with standard doses of weekly paclitaxel in patients with locally advanced or metastatic solid tumors with expansion in advanced breast cancerGonzalez-Angulo A, Krop I, Piha-Paul S, Li Y, Culotta K, Moulder-Thompson S, Tsimberidou A, Velez-Bravo V, Madden T, Norberg L, Doyle A, Winder E, Mills G, Meric-Bernstam F, Kurzrock R. Abstract LB-231: Phase Ib dose escalation and biomarker study of MK2206 in combination with standard doses of weekly paclitaxel in patients with locally advanced or metastatic solid tumors with expansion in advanced breast cancer Cancer Research 2012, 72: lb-231-lb-231. DOI: 10.1158/1538-7445.am2012-lb-231.
  • E6. Can an international consensus meeting change the future of advanced breast cancer patients? Highlights from ABC1 Consensus MeetingCardoso F, Winer E, Norton L, Gomis R, Krop I, Harbeck N, Costa A. E6. Can an international consensus meeting change the future of advanced breast cancer patients? Highlights from ABC1 Consensus Meeting European Journal Of Cancer 2012, 48: s13-s14. DOI: 10.1016/s0959-8049(12)70057-6.
  • P1-06-23: Changes in Gene Expression after One Dose of Trastuzumab (T) in HER2+ Breast Cancer Cell Lines Predict Novel Pathways of Response in HER2 Positive Early Stage Breast Cancer.Sprecher E, Lezon-Geyda K, Sarkar S, Bossuyt V, Narayaan M, Kumar A, Krop I, Winer E, Tuck D, Kleinstein S, Harris L. P1-06-23: Changes in Gene Expression after One Dose of Trastuzumab (T) in HER2+ Breast Cancer Cell Lines Predict Novel Pathways of Response in HER2 Positive Early Stage Breast Cancer. Cancer Research 2011, 71: p1-06-23-p1-06-23. DOI: 10.1158/0008-5472.sabcs11-p1-06-23.
  • P1-17-02: A Phase 1/2 Study of SAR245408 (S08) in Combination with Trastuzumab (T) or Paclitaxel (P) and T in Patients with HER2+ Metastatic Breast Cancer (MBC) Who Progressed on a Previous T-Based Regimen.Tolaney S, Burris H, Gartner E, Mayer I, Saura C, Maurer M, DeCillis A, Ruiz-Soto R, Lager J, Winer E, Krop I. P1-17-02: A Phase 1/2 Study of SAR245408 (S08) in Combination with Trastuzumab (T) or Paclitaxel (P) and T in Patients with HER2+ Metastatic Breast Cancer (MBC) Who Progressed on a Previous T-Based Regimen. Cancer Research 2011, 71: p1-17-02-p1-17-02. DOI: 10.1158/0008-5472.sabcs11-p1-17-02.
  • P2-18-02: Cardiac Outcomes of Patients on Adjuvant Weekly Paclitaxel (T) and Trastuzumab (H) for Node Negative, HER2 Positive Breast Cancer (BCA).Dang C, Tolaney S, Najita J, Gelman R, Yardley D, Marcom K, Albain K, Rugo H, Miller K, Ellis M, Shapira I, Wolff A, Carey L, Vahdat L, Burdette-Radoux S, Budd T, Krop I, Burstein H, Hudis C, Winer E. P2-18-02: Cardiac Outcomes of Patients on Adjuvant Weekly Paclitaxel (T) and Trastuzumab (H) for Node Negative, HER2 Positive Breast Cancer (BCA). Cancer Research 2011, 71: p2-18-02-p2-18-02. DOI: 10.1158/0008-5472.sabcs11-p2-18-02.
  • PD05-07: Prospective Validation and Characterization of HER2 Positive Circulating Tumor Cells in Patients with HER2 Negative Metastatic Breast Cancer.Olson E, Flores L, Najita J, Curley C, Jeong J, Murray K, Savoie J, Winer E, Krop I. PD05-07: Prospective Validation and Characterization of HER2 Positive Circulating Tumor Cells in Patients with HER2 Negative Metastatic Breast Cancer. Cancer Research 2011, 71: pd05-07-pd05-07. DOI: 10.1158/0008-5472.sabcs11-pd05-07.
  • PD09-04: A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of the PI3-Kinase Inhibitor GDC-0941 in Combination with Paclitaxel and Bevacizumab in Patients with Locally Recurrent or Metastatic Breast Cancer.Schöffski P, De Benedictis E, Gendreau S, Gianni L, Krop I, Levy G, Ware J, Wildiers H, Winer E. PD09-04: A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of the PI3-Kinase Inhibitor GDC-0941 in Combination with Paclitaxel and Bevacizumab in Patients with Locally Recurrent or Metastatic Breast Cancer. Cancer Research 2011, 71: pd09-04-pd09-04. DOI: 10.1158/0008-5472.sabcs11-pd09-04.
  • P1-09-03: Prevalence of Germline TP53 Mutations in Young Women with HER2−Positive Breast Cancer.Dick M, Masciari S, Miron A, Miron P, Foley K, Gelman R, Dillon D, Richardson A, Verselis S, Lypas G, Krop I, Garber J. P1-09-03: Prevalence of Germline TP53 Mutations in Young Women with HER2−Positive Breast Cancer. Cancer Research 2011, 71: p1-09-03-p1-09-03. DOI: 10.1158/0008-5472.sabcs11-p1-09-03.
  • New and future therapies for HER-2+ advanced breast cancerKrop I. New and future therapies for HER-2+ advanced breast cancer The Breast 2011, 20: s16. DOI: 10.1016/j.breast.2011.08.015.
  • TBCRC 003: Phase II trial of trastuzumab (T) and lapatinib (L) in patients (pts) with HER2+ metastatic breast cancer (MBC).Lin N, Mayer I, Najita J, Hobday T, Falkson C, Dees E, Rimawi M, Nanda R, Gelman R, Josephs K, Richardson A, Flores L, Van Den Abbeele A, Yap J, Arteaga C, Wolff A, Krop I, Winer E. TBCRC 003: Phase II trial of trastuzumab (T) and lapatinib (L) in patients (pts) with HER2+ metastatic breast cancer (MBC). Journal Of Clinical Oncology 2011, 29: 527-527. DOI: 10.1200/jco.2011.29.15_suppl.527.
  • The role of EGFR amplification in trastuzumab resistance: A correlative analysis of TBCRC003.Krop I, Flores L, Najita J, Mayer I, Hobday T, Falkson C, Arteaga C, Wolff A, Dees E, Rimawi M, Nanda R, Josephs K, Lin N, Winer E. The role of EGFR amplification in trastuzumab resistance: A correlative analysis of TBCRC003. Journal Of Clinical Oncology 2011, 29: 528-528. DOI: 10.1200/jco.2011.29.15_suppl.528.
  • A semi-physiologic population pharmacokinetic/pharmacodynamic (PK/PD) model of thrombocytopenia (TCP) characterizing the effect of trastuzumab-DM1 (T-DM1) on platelet counts in patients with HER2-positive MBC.Bender B, Schaedeli Stark F, Joshi A, Chu Y, Rugo H, Krop I, Girish S, Gupta M. A semi-physiologic population pharmacokinetic/pharmacodynamic (PK/PD) model of thrombocytopenia (TCP) characterizing the effect of trastuzumab-DM1 (T-DM1) on platelet counts in patients with HER2-positive MBC. Journal Of Clinical Oncology 2011, 29: 605-605. DOI: 10.1200/jco.2011.29.15_suppl.605.
  • Abstract 4719: Dynamic changes in gene expression after one dose of trastuzumab (T) reveal novel biomarkers of response to combination therapy in HER2 positive early stage breast cancerHarris L, Sprecher E, Wei-Gu L, Lezon-Geyda K, Sakar S, Krop I, Winer E, Tuck D. Abstract 4719: Dynamic changes in gene expression after one dose of trastuzumab (T) reveal novel biomarkers of response to combination therapy in HER2 positive early stage breast cancer Cancer Research 2011, 71: 4719-4719. DOI: 10.1158/1538-7445.am2011-4719.
  • Association between response to brief trastuzumab exposure in cell lines and early stage HER2+ breast tumorsSprecher E, Sarkar S, Kleinstein S, Narayan M, Winer E, Tuck D, Lezon-Geyda K, Krop I, Harris L. Association between response to brief trastuzumab exposure in cell lines and early stage HER2+ breast tumors 2011, 446-450. DOI: 10.1145/2147805.2147867.
  • Abstract P3-14-08: Responses to Subsequent Anti-HER2 Therapy after Treatment with Trastuzumab-DM1 in Women with HER2-Positive Metastatic Breast CancerOlson E, Lin N, DiPiro P, Najita J, Krop I, Winer E, Burstein H. Abstract P3-14-08: Responses to Subsequent Anti-HER2 Therapy after Treatment with Trastuzumab-DM1 in Women with HER2-Positive Metastatic Breast Cancer Cancer Research 2010, 70: p3-14-08-p3-14-08. DOI: 10.1158/0008-5472.sabcs10-p3-14-08.
  • Abstract P6-15-02: A Phase Ib Study Evaluating Safety, Tolerability, Pharmacokinetics (PK), and Activity of the Phosphoinositide-3 Kinase (PI3K) Inhibitor GDC-0941 in Combination with Trastuzumab-MCC-DM1 (T-DM1) in Patients with Advanced HER2-Positive Breast CancerKrop I, Wolff A, Winer E, Miller K, Park B, Ware J, Holden S, Levy G, Derynck M, Storniolo A. Abstract P6-15-02: A Phase Ib Study Evaluating Safety, Tolerability, Pharmacokinetics (PK), and Activity of the Phosphoinositide-3 Kinase (PI3K) Inhibitor GDC-0941 in Combination with Trastuzumab-MCC-DM1 (T-DM1) in Patients with Advanced HER2-Positive Breast Cancer Cancer Research 2010, 70: p6-15-02-p6-15-02. DOI: 10.1158/0008-5472.sabcs10-p6-15-02.
  • Abstract PD07-08: Integrated Genomic Analysis before and after Brief Exposure to Trastuzumab (T): The11q13 and 17q12 Amplicons Are Associated with Response to T+Chemotherapy in Early Stage HER2 Positive Breast CancerHarris L, Liu Z, Li A, Sprecher E, Sarkar S, Lezon-Geyda K, Krop I, Winer E, Tuck D. Abstract PD07-08: Integrated Genomic Analysis before and after Brief Exposure to Trastuzumab (T): The11q13 and 17q12 Amplicons Are Associated with Response to T+Chemotherapy in Early Stage HER2 Positive Breast Cancer Cancer Research 2010, 70: pd07-08-pd07-08. DOI: 10.1158/0008-5472.sabcs10-pd07-08.
  • Abstract P3-14-10: A Dose-Escalation Study of Trastuzumab-DM1 (T-DM1), Paclitaxel (T), and Pertuzumab (P) in Patients with HER2-Positive, Locally Advanced or Metastatic Breast Cancer (MBC) Previously Treated with a Trastuzumab-Containing RegimenKrop I, Modi S, Elias A, LoRusso P, Choi Y, Lu M. Abstract P3-14-10: A Dose-Escalation Study of Trastuzumab-DM1 (T-DM1), Paclitaxel (T), and Pertuzumab (P) in Patients with HER2-Positive, Locally Advanced or Metastatic Breast Cancer (MBC) Previously Treated with a Trastuzumab-Containing Regimen Cancer Research 2010, 70: p3-14-10-p3-14-10. DOI: 10.1158/0008-5472.sabcs10-p3-14-10.
  • Abstract P3-14-22: Pharmacokinetics (PK) of Trastuzumab-DM1 (T-DM1) and Paclitaxel (T) in Patients with HER2-Positive Locally Advanced or Metastatic Breast Cancer (MBC) Previously Treated with a Trastuzumab-Containing RegimenLu D, Krop I, Modi S, Elias A, LoRusso P, Huang J, Lu M, Girish S. Abstract P3-14-22: Pharmacokinetics (PK) of Trastuzumab-DM1 (T-DM1) and Paclitaxel (T) in Patients with HER2-Positive Locally Advanced or Metastatic Breast Cancer (MBC) Previously Treated with a Trastuzumab-Containing Regimen Cancer Research 2010, 70: p3-14-22-p3-14-22. DOI: 10.1158/0008-5472.sabcs10-p3-14-22.
  • Abstract P6-15-03: Phase Ib Trial of the Gamma Secretase Inhibitor (GSI), MK-0752 Followed by Docetaxel in Locally Advanced or Metastatic Breast CancerSchott A, Chang J, Krop I, Griffith K, Layman R, Hayes D, Wicha M. Abstract P6-15-03: Phase Ib Trial of the Gamma Secretase Inhibitor (GSI), MK-0752 Followed by Docetaxel in Locally Advanced or Metastatic Breast Cancer Cancer Research 2010, 70: p6-15-03-p6-15-03. DOI: 10.1158/0008-5472.sabcs10-p6-15-03.
  • Phase I/II trial of everolimus (RAD001) and trastuzumab in patients with trastuzumab-resistant, HER2-overexpressing breast cancer.Morrow P, Wulf G, Booser D, Moore J, Flores P, Krop I, Winer E, Hortobagyi G, Yu D, Esteva F. Phase I/II trial of everolimus (RAD001) and trastuzumab in patients with trastuzumab-resistant, HER2-overexpressing breast cancer. Journal Of Clinical Oncology 2010, 28: 1014-1014. DOI: 10.1200/jco.2010.28.15_suppl.1014.
  • Phase II trial of preoperative vinorelbine/trastuzumab (VH) or docetaxel/carboplatin/trastuzumab (TCH) in HER2-positive breast cancer with analysis of resistance mechanisms.Krop I, Flores L, Tuck D, Ryan P, Partridge A, Morganstern D, Najita J, lezon-Geyda K, Winer E, Harris L. Phase II trial of preoperative vinorelbine/trastuzumab (VH) or docetaxel/carboplatin/trastuzumab (TCH) in HER2-positive breast cancer with analysis of resistance mechanisms. Journal Of Clinical Oncology 2010, 28: 549-549. DOI: 10.1200/jco.2010.28.15_suppl.549.
  • TBCRC 003: Phase II trial of trastuzumab (T) and lapatinib (L) in patients (pts) with HER2+ metastatic breast cancer (MBC).Lin N, Mayer I, Hobday T, Falkson C, Dees E, Nanda R, Krop I, Rimawi M, Wolff A, Winer E. TBCRC 003: Phase II trial of trastuzumab (T) and lapatinib (L) in patients (pts) with HER2+ metastatic breast cancer (MBC). Journal Of Clinical Oncology 2010, 28: tps132-tps132. DOI: 10.1200/jco.2010.28.15_suppl.tps132.
  • Quantitative assessment of diagnostic markers and correlations with efficacy in two phase II studies of trastuzumab-DM1 (T-DM1) for patients (pts) with metastatic breast cancer (MBC) who had progressed on prior HER2-directed therapy.LoRusso P, Krop I, Burris H, Vukelja S, Miller K, Zheng M, Chu Y, Lu M, Amler L, Rugo H. Quantitative assessment of diagnostic markers and correlations with efficacy in two phase II studies of trastuzumab-DM1 (T-DM1) for patients (pts) with metastatic breast cancer (MBC) who had progressed on prior HER2-directed therapy. Journal Of Clinical Oncology 2010, 28: 1016-1016. DOI: 10.1200/jco.2010.28.15_suppl.1016.
  • Comparison of the Cellsearch Profile Kit (CPK) with the Standard Cellsearch Epithelial Kit (CEK) Demonstrates the CPK Produces Higher Circulating Tumor Cell (CTC) Yields and Is Better Suited for Use in Obtaining CTC's for Molecular Characterization.Flores L, Kindelberger D, Ligon A, Cappeletti M, Fiorentino M, Loda M, Cibas E, Janne P, Krop I. Comparison of the Cellsearch Profile Kit (CPK) with the Standard Cellsearch Epithelial Kit (CEK) Demonstrates the CPK Produces Higher Circulating Tumor Cell (CTC) Yields and Is Better Suited for Use in Obtaining CTC's for Molecular Characterization. Cancer Research 2009, 69: 3003-3003. DOI: 10.1158/0008-5472.sabcs-09-3003.
  • A Phase II Study of Trastuzumab-DM1 (T-DM1), a Novel HER2 Antibody–Drug Conjugate, in HER2+ Metastatic Breast Cancer (MBC) Patients Previously Treated with Conventional Chemotherapy, Lapatinib and Trastuzumab.Krop I, LoRusso P, Miller K, Modi S, Yardley D, Rodriguez G, Agresta S, Zheng M, Amler L, Rugo H. A Phase II Study of Trastuzumab-DM1 (T-DM1), a Novel HER2 Antibody–Drug Conjugate, in HER2+ Metastatic Breast Cancer (MBC) Patients Previously Treated with Conventional Chemotherapy, Lapatinib and Trastuzumab. Cancer Research 2009, 69: 5090-5090. DOI: 10.1158/0008-5472.sabcs-09-5090.
  • 5020 Pharmacokinetics (PK), safety, and efficacy of trastuzumab (T)-DM1, a HER2 antibody-drug conjugate (ADC), in patients with HER2+ metastatic breast cancer (MBC): phase I and phase II trial resultsBurris H, Vukelja S, Krop I, Modi S, Klencke B, Girish S, Sliwkowski M, Dresser M, Phillips G, Rugo H. 5020 Pharmacokinetics (PK), safety, and efficacy of trastuzumab (T)-DM1, a HER2 antibody-drug conjugate (ADC), in patients with HER2+ metastatic breast cancer (MBC): phase I and phase II trial results European Journal Of Cancer Supplements 2009, 7: 266-267. DOI: 10.1016/s1359-6349(09)70912-7.
  • Personalizing treatment in early-stage breast cancer: The role of standard clinical factors and genomic information in adjuvant chemotherapy decision makingGold J, Najita J, Lester S, Richardson A, Morganstern D, Chen W, Partridge A, Krop I, Winer E, Burstein H. Personalizing treatment in early-stage breast cancer: The role of standard clinical factors and genomic information in adjuvant chemotherapy decision making Journal Of Clinical Oncology 2009, 27: 572-572. DOI: 10.1200/jco.2009.27.15_suppl.572.
  • Quantitative assessment of HER2 status and correlation with efficacy for patients (pts) with metastatic breast cancer (MBC) in a phase II study of trastuzumab-DM1 (T-DM1)Krop I, Burris H, Rugo H, O'Shaughnessy J, Vogel C, Amler L, Strauss A, Wong E, Klencke B, Pippen J. Quantitative assessment of HER2 status and correlation with efficacy for patients (pts) with metastatic breast cancer (MBC) in a phase II study of trastuzumab-DM1 (T-DM1) Journal Of Clinical Oncology 2009, 27: 1003-1003. DOI: 10.1200/jco.2009.27.15_suppl.1003.
  • A phase II study of ixabepilone plus trastuzumab for metastatic HER2-positive breast cancer.Tolaney S, Najita J, Chen W, Savoie J, Fornier M, Krop I, Winer E, Bunnell C. A phase II study of ixabepilone plus trastuzumab for metastatic HER2-positive breast cancer. Cancer Research 2009, 69: 3137. DOI: 10.1158/0008-5472.sabcs-3137.
  • A phase I study of weekly dosing of trastuzumab-DM1 (T-DM1) in patients with advanced HER2+ breast cancer.Krop I, Mita M, Burris H, Birkner M, Girish S, Tibbitts J, Holden S, Lutzker S, Modi S. A phase I study of weekly dosing of trastuzumab-DM1 (T-DM1) in patients with advanced HER2+ breast cancer. Cancer Research 2009, 69: 3136. DOI: 10.1158/0008-5472.sabcs-3136.
  • Identification of novel HER2 splice variants in breast cancerBorras A, Rogers A, Kuang Y, Flores L, Distel R, Krop I. Identification of novel HER2 splice variants in breast cancer Journal Of Clinical Oncology 2008, 26: 22010-22010. DOI: 10.1200/jco.2008.26.15_suppl.22010.
  • A phase I study of trastuzumab-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with advanced HER2+ breast cancer (BC)Beeram M, Burris H, Modi S, Birkner M, Girish S, Tibbitts J, Holden S, Lutzker S, Krop I. A phase I study of trastuzumab-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with advanced HER2+ breast cancer (BC) Journal Of Clinical Oncology 2008, 26: 1028-1028. DOI: 10.1200/jco.2008.26.15_suppl.1028.
  • A phase I study of weekly dosing of trastuzumab-DM1 (T-DM1) in patients (pts) with advanced HER2+ breast cancer (BC)Holden S, Beeram M, Krop I, Burris H, Birkner M, Girish S, Tibbitts J, Lutzker S, Modi S. A phase I study of weekly dosing of trastuzumab-DM1 (T-DM1) in patients (pts) with advanced HER2+ breast cancer (BC) Journal Of Clinical Oncology 2008, 26: 1029-1029. DOI: 10.1200/jco.2008.26.15_suppl.1029.
  • A phase II study of oral enzastaurin in patients with metastatic breast cancer previously treated with an anthracycline and a taxane-containing regimen: HOG BRE05–97Krop I, Miller K, Zon R, Isakoff S, Schneider C, Yu M, Johnson C, Vaughn L, Shonukan O, Sledge G. A phase II study of oral enzastaurin in patients with metastatic breast cancer previously treated with an anthracycline and a taxane-containing regimen: HOG BRE05–97 Journal Of Clinical Oncology 2008, 26: 1004-1004. DOI: 10.1200/jco.2008.26.15_suppl.1004.
  • 2118 POSTER A phase I study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with HER2+ metastatic breast cancerKrop I, Beeram M, Modi S, Rabbee N, Girish S, Tibbitts J, Holden S, Lutzker S, Burris H. 2118 POSTER A phase I study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with HER2+ metastatic breast cancer European Journal Of Cancer Supplements 2007, 5: 219. DOI: 10.1016/s1359-6349(07)70880-7.
  • A phase I study of trastuzumab-MCC-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (BC)Beeram M, Krop I, Modi S, Tolcher A, Rabbee N, Girish S, Tibbitts J, Holden S, Lutzker S, Burris H. A phase I study of trastuzumab-MCC-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (BC) Journal Of Clinical Oncology 2007, 25: 1042-1042. DOI: 10.1200/jco.2007.25.18_suppl.1042.
  • Phase I pharmacokinetic (PK), and pharmacodynamic (PD) trial of the novel oral Notch inhibitor MK-0752 in patients (pts) with advanced breast cancer (BC) and other solid tumorsKrop I, Kosh M, Fearen I, Savoie J, Dallob A, Matthews C, Stone J, Winer E, Freedman S, Lorusso P. Phase I pharmacokinetic (PK), and pharmacodynamic (PD) trial of the novel oral Notch inhibitor MK-0752 in patients (pts) with advanced breast cancer (BC) and other solid tumors Journal Of Clinical Oncology 2006, 24: 10574-10574. DOI: 10.1200/jco.2006.24.18_suppl.10574.
  • Early Breast Cancer (Stage I and Stage II): Tailored Systemic Therapy for Endocrine-Responsive Breast CancerKrop I, Winer E. Early Breast Cancer (Stage I and Stage II): Tailored Systemic Therapy for Endocrine-Responsive Breast Cancer 2006, 327-348. DOI: 10.1007/978-3-540-28266-2_17.
  • HIN-1, an inhibitor of cell growth, invasion, and AKT1 activationKrop I, Parker M, Qimron N, Porter D, Polyak K. HIN-1, an inhibitor of cell growth, invasion, and AKT1 activation Breast Cancer Research 2005, 7: p4.04. PMCID: PMC4233555, DOI: 10.1186/bcr1134.